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Abstract

Charcot-Marie-Tooth (CMT) Disease is a group of peripheral neuropathies affecting 1 in
2500 individuals. It is characterized by progressive sensory loss and distal muscle
weakness affecting mostly the lower extremities that lead to foot deformities. More than
thirty genetic loci are affected in this disease, products of which are involved in axonal
trafficking. Rab7 is one such gene that gets mutated in CMT Type2B disease. To date
four missense mutants of Rab7 have been identified. L129F, K157N, N161T and V162M
amino acid substitutions of Rab7 occur in highly conserved regions. Rab7 is a ubiquitous
protein but only the peripheral nerves get affected in this disease. This calls for an urgent
need to study the pathogenesis of CMT2B disease, the awry molecular mechanisms of
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which remain unknown. This thesis details for the first time the impaired trafficking,
altered endosomal and nuclear signaling caused by Rab7CMT2B mutants through
differential interaction with effector proteins. The work provides foundation for
identifying potential molecular targets for therapeutic interventions in combating this
disease.
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Chapter 1: Introduction
Genetics of Neuropathies
Charcot-Marie-Tooth (CMT) disease is a clinically diverse, heterogenous group of
inherited peripheral neuropathies that typically affect the peripheral nervous system with
a prevalence of 40 in 100,000 individuals (1-3). These diseases affect both the sensory
and motor neurons and hence are also known as hereditary Motor and Sensory
Neuropathies. CMT disease is divided into Type 1 characterized by a demyelinating
phenotype and Type 2 characterized by distinct axonal loss. Both these subtypes result in
progressive sensory loss, distal muscle weakness, affecting mostly the lower extremities
that lead to foot deformities (4-6). Type 1 subtypes affect myelination or cell
communication principally in Schwann cells and include CMT1A-B, CMT3
(hypertrophic neuropathy of Dejerine-Sottas),some forms of CMT4A, CMT4B and
CMTX (7). The CMT Type 2 is caused by mutations in 15 genetic loci that cause
autosomal dominant or recessive forms of the disease (8). Type 2 subtypes result in
axonal degeneration and include CMT2A-G, I-L, and intermediate CMT, DI-CMTB (9).
The similarities in disease manifestation resulting from mutations in over thirty known
genes may be ascribed to the extensive interdependence of Schwann cells and neurons,
and to the fact that the gene products are operative on common pathways (Figure 1). For
example, multiple CMT disease associated genes affect proteins that regulate endocytic
membrane transport and thereby impact neurons and Schwann cells in the maintenance of
axon viability.
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Figure 1: Charcot-Marie-Tooth Disease is a neurodegenerative disorder caused by
defects in endocytosis. Charcot-Marie-Tooth (CMT) disease is heterogenous group of
peripheral neuropathy affecting more than thirty genetic loci coding for proteins playing
important roles in endocytic trafficking. The above diagram shows the different proteins
mutant in this disease and their consequent phenotypic effects.
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Systematic genetic screening in CMT affected patients enables diagnosis of 50-70% of
patients suggesting that additional genes are involved in peripheral neuropathies (10).
CMT patients have symmetric distal amyotrophy in lower limbs and hands, foot
deformities and distal sensory loss (11). Spine deformities are not common but are seen
in specific subtypes like CMT type 4C (12). CMT disease typically sets in the first or
second decade of life and primarily affects the lower extremities.
According to the motor nerve conduction velocity (MNCV) and compound muscle action
potential CMT can be divided into two types: demyelinating (CMT1) and axonal
(CMT2). The demyelinating forms usually have MNCV lower than 38m/s in the upper
extremities and the axonal form has higher MNCV although the compound muscle action
potential is also affected in this form. The intermediate form of CMT disease is
characterized by MNCV in the range of 38-45m/s (13-16).
About 90% of the dominant forms of CMT disease are more prevalent in Western
countries whereas 30-50% of the recessive forms occur in countries with high incidence
of consanguinity (eg. Mediterranean Basin, European gypsies) (17). A detailed list of the
different forms of CMT disease is given in Table1.
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Table1: Different forms of CMT Disease

Inheritance Demyelinating Forms

IntermediateForms Axonal Forms

Form

Genes

Form

Autosomal

CMT1A

PMP22

DI-

Dominant

CMT1B

MPZ

CMTA

CMT1C

LITAF

CMT1D
CMT1F

Autosomal

CMT4A

Form

Genes

CMT2A1/2

MFN2/KIF1B

DNM2

CMT2B

RAB7

DI-

YARS

CMT2C

TRPV4

EGR2

CMTB

MPZ

CMT2D

GARS

NEFL

DI-

INF2

CMT2E

NEFL

CMTC

CMT2F

HSP27

DI-

CMT2G

?

CMTD

CMT2I/2J

MPZ

DI-

CMT2K

GDAP1

CMTE

CMT2L

HSP22

CMT2M

DNM2

CMT2N

AARS

CMT2O

DYNC1H1

CMT2P

LRSAM1

GDAP1

RI-

ARCMT2A2 MFN2
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Genes

Recessive

X-linked

CMT4B1 MTMR2

CMTA

GDAP1 CMT2B1

LMNA

CMT4B2 MTMR13

CMT2B2

MED25

CMT4C

SH3CT2

CMT2H

GDAP1

CMT4D

NDRG1

CMT2P

LRSAM1

CMT4E

EGR2/MPZ

CMT4F

PRX

CMT4G

HK1

CMT4H

FGD4

CMT4J

FIG4

CMTX1 GJB1

Dominant
X-linked

CMTX2 ?

Recessive

CMTX3 ?
CMTX4 ?
CMTX5 PRPS1
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Charcot-Marie-Tooth disease affects both the Schwann cells and the axons. The axonal
forms of CMT affect both the dorsal root ganglion sensory neurons and spinal motor
neurons. Axons can grow as long as 1meter from the soma to sensory receptors in the
muscle or skin and to neuromuscular junctions with skeletal muscles (18). This is an
Achilles’ heel for the neuron as minor differences in endocytic trafficking can have a
profound overall impact on its long term survival.
The complexity of CMT disease is underscored by the fact that more than thirty genetic
loci are affected. Mutations in DYNC1H1 gene that encodes the dynein heavy chain
protein or NEFL and LMNA genes encoding the neurofilament and LaminA/C
responsible for neurofilament homeostasis cause impaired axonal transport in CMT
disease. Mutations in MFN2 and GDAP1 genes responsible for mitochondrial functions
lead to CMT due to energy requirements for endocytic transport. There is close cooperativity between Rab32 and mitochondrial function (19, 20). Other genes responsible
for protein synthesis and turnover (GARS, AARS, LRSAM1), calcium homeostasis
(TRPV4), myelin assembly (MPZ), gene expression regulation (MED25) and endocytosis
(Rab7 and DNM2) lead to the severe axonal forms of the disease (21, 22).

Rab7CMT2B Disease
Rab7 belongs to the Ras superfamily of GTPases that play a crucial role in cellular
trafficking, signaling and cytoskeletal regulation. Rab7 controls the transport from early
endosomes

to

late

endosomes,

lysosome
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maturation,

phagolysosomal

and

autophagosomal biogenesis. It also plays a critical role in growth factor mediated cell
survival and apoptosis (23).

Mutation or dysfunction in the Rab7 gene causes endocytic trafficking disorders leading
to Charcot–Marie-Tooth Type 2B (CMT2B) also known as heriditary Motor and Sensory
Neuropathy type IIB. It causes prominent loss of sensory neurons and is often
characterized by frequently occurring infections and ulcers hence it is also termed as
ulceromutilating neuropathy (24). To date, four mutants associated with Rab7have been
implicated in this disease. These are L129F, K157N, N161T and V162M, all amino acid
substitutions of highly conserved amino acid residues (25-27) (Figure 2). All these
missense mutants reside outside the nucleotide binding pocket and adjacent to the switch
II region in the C-terminal portion of the protein (28). Biochemical studies of the
Rab7CMT2B mutants indicate that the disease mutants have reduced GTPase activity and
predominantly occur in the GTP-bound state; hence they are presumed to be more active
than the wild-type protein (29, 30).
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Figure 2: Structure of Rab7 with CMT2B disease mutants. Rab7 structure indicates
the amino acid residues L129F, K157N, N161T and V162M substitutions in CharcotMarie-Tooth Type2B Disease (Image: Oleg Ursu).
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Rab7-the master regulator of endocytic traffic
Rab7 is one of the most studied endocytic Rab GTPases due to its pivotal roles in
shunting molecules for recycling through the Golgi, back to the plasma membrane or to
degradation (Figure 3). Typical of Ras-related GTPases, Rab7 undergoes a cycle of
membrane association and dissociation that is closely linked to nucleotide binding and
hydrolysis (31). In the membrane associated state, Rab7 is GTP-bound and active, while
upon hydrolysis the GDP-bound Rab7 is inactive and recycles to the cytoplasm. The
GDP/GTP dependent activation cycle is regulated by two sets of proteins, the guanine
nucleotide exchange factors (GEFs) that catalyze the conversion to the active GTP-bound
state and the GTPase activating proteins (GAPs) that stimulate the GTPase activity of the
Rab protein to convert it to the inactive GDP-bound state. Early reports suggested Vps39
functioned as a Rab7 GEF. More recently, studies in yeast and C. elegans indicate that
Ypt7p/Rab7 activation is linked to endosome conversion involving coordinate
inactivation and loss of the early endosomal Rab5 and acquisition and activation of the
late endosomal Rab7 through large multimeric complexes with overlapping components
(Figure 4) (32).

9	
  
	
  

Figure 3: Intracellular trafficking pathways associated with Rab7. Rab7 regulates
cargo trafficking to the lysosomes for degradation via late endosomes, cargo recycling
through the Golgi back to the plasma membrane, autophagy, phagolysosome fusion and
osteoclast-mediated bone resorption.
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The activation of Rab7 is dynamically regulated through differential interactions of
proteins first identified to be important in autophagy called Rubicon (RUN domain and
cysteine-rich domain containing Beclin 1-interacting protein) and UVRAG (33,
34).Rubicon, a regulatory component of the phosphatidylinositol 3-kinase complex
(PI3KC3;hVps34/hVps15), can bind and sequester UVRAG and thereby block Rab7
mediated transport (35, 36). Conversely, membrane-bound, active Rab7 can relieve the
inhibition of its activation by binding Rubicon (33). Proteins of the Tre-Bub-CDC16
(TBC) family function as GTPase-activating proteins that stimulate nucleotide
hydrolysis. Three family members (TBC1D2/Armus, TBC1D5, and TBC1D15) have all
been shown to stimulate Rab7 nucleotide hydrolysis and may regulate Rab7 involvement
in discrete functions in coordination with specific signaling (37-39). For example, on
endosomes the recycling of mannose 6-phosphate receptor to the Golgi via retromer is
thought to be regulated by Rab7/TBC1D5, while the disassembly of adherens junctions
and degradation of E-cadherin depends on signal integration of Arf6 and a
Rac1/TBC1D2/Rab7 complex. As illustrated by the specific examples given, the
facilitated nucleotide binding and hydrolysis cycle brings about conformational changes
in Rab7 that modulate its activity and localization.

11	
  
	
  

Figure 4: Rab7 activation cycle. Newly synthesized Rab7 is prenylated by
geranylgeranyl transferase (GGT) and delivered to endosomal membranes by Rab escort
protein (REP), thereafter Rab7 membrane cycling is facilitated by GDP dissociation
inhibitor (GDI); pathways that are common to all Rab GTPases. A GDI displacement
factor (GDF) has been implicated in membrane transfer of late endocytic Rab9 and Rab7.
Rab7 activation is closely linked to Rab5 inactivation in a conversion process that
involves Mon1. A Vps39-Mon1-Ccz1 complex likely acts as a guanine nucleotide
exchange factor (GEF) to promote activation, while TBC1D5 or TBC1D15 act as
GTPase-activating proteins (GAPs) to promote hydrolysis and inactivation. Active, GTPbound Rab7 acts as a scaffold for sequentially binding multiple effectors
phosphoinositide 3-kinase (PI3K, Vps34/Vps15), HOPS, Rubicon, UVRAG, among
others to promote cargo selection, cytoskeletal translocation and membrane fusion.
12	
  
	
  

Besides activation through nucleotide binding, another level of regulation occurs through
membrane localization. Membrane localization is dependent on post-translational
modification with a lipid anchor (prenylation). Nascent Rab7 synthesized on cytosolic
ribosomes is inactive and GDP-bound. Prenylation on two C-terminal cysteine residues is
mediated by the universal Rab geranyl geranyl transferase, through recognition of the last
nine amino acid residues of Rab7 (40). The Rab escort protein (REP) serves as the
intermediary for Rab7 presentation to the prenylating enzyme and first-time membrane
association (28). GDP dissociation inhibitor (GDI) functions as a universal Rab recycling
factor, binding preferentially to doubly prenylated, GDP-bound Rab7 (41). GDI binding
masks the isoprenyl anchor in the cytosol and renders Rab7 membrane association a
reversible process that is closely linked to the nucleotide bound status, based on the fact
that GDI has a 3 order of magnitude higher affinity for Rab7-GDP than Rab7-GTP (42).
A GDI-displacement factor (GDF) has been implicated in GDI release during endosomal
Rab membrane association, though GEF proteins may also perform this function in
conjunction with nucleotide exchange (42). Once on the membrane and in the GTPbound state, Rab7 interacts with diverse effectors to carry out specific functions in late
endocytic membrane trafficking.

Like other Rab GTPases, Rab7 GTPase is a molecular switch that cycles between a GTPbound active state and a GDP-bound inactive state and serve as platforms to regulate
membrane trafficking and intracellular signaling in a spatiotemporal manner (43-46).
Rab7has a low molecular size (23kDa); however structural analyses reveal it has multiple
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interaction surfaces through which it interacts with different effector proteins and
regulatory molecules. The Rab7CMT2B disease mutants have been proposed to have a
misregulated Rab7 activation cycle. According to this model, decreased affinity of the
mutant Rab7 for GDP permits GTP exchange to occur independent of GEF activity and
GTP dissociation to occur independent of GAP activity to inactivate the protein.
Interestingly, since the relative affinity of the disease mutants for GTP is higher than
GDP these presumably bind to GTP and undergo multiple activation cycles before
membrane extraction. This would result in a subtle increase in the GTP to GDP ratio and
increase Rab7 residence time on the target membranes thereby facilitating Rab7 binding
to host of different effectors potentially preventing progression to the next phase due to
reduced GTP hydrolysis (47). This might slow the trafficking of signaling endosomes and
reduce temporal progression and fusion with lysosomes by differential interaction with
effectors.

Rab7 Effectors in the Control of Endocytic Trafficking
Over the years, many effector proteins have been identified to interact specifically with
active GTP-bound Rab7. Rab7 effectors orchestrate events ranging from cargo selection
to microtubule translocation to downstream membrane tethering and endosomal
membrane fusion (Figure 5). Emerging concepts are that Rab7 activation contributes to
the dynamic assembly of large protein complexes in a spatially and temporally regulated
manner (32). Specific protein complexes serve discrete functions in the transport process,
yet handoffs and multiple layers of regulation are common. The importance of
maintaining transport fidelity is evidenced by the increasing numbers of human diseases
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attributable to defects in endosomal trafficking and Rab7 specifically (Charcot-MarieTooth disease type 2) (31, 48) (Figure 6).
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Figure 5: Rab7 regulated trafficking by coordinating with host of effectors. (a)
Cargo recycling from early endosomes to the Golgi entails sequential Rab5 (via
CORVET) and Rab7 activation and Rab7 mediated recruitment of a complex of VIPs
proteins (26/29/35) known as retromer. Rab5 activation can be positively modulated by
EGF receptor signaling. (b) Transport to lysosomes. Rab7 cooperates with the Dyn2CIN85 complex to regulate signaling and lysosomal degradation of the ligand-receptor
(EGF-EGF receptor) complex. Bidirectional transport on microtubules depends on
kinesin and dynein motors. (c) Transport from early to late endosomes. Growth factor
receptor signaling is intimately coupled to endocytic transport. As illustrated, nerve
growth factor receptor TrkA and EGF receptor associate with MAPK on endosomes are
translocated bidirectionally on microtubules. Transport toward perinuclear late
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endosomes occurs through association with the Rab7 effector RILP and the p150/dynein
motor complex. Association with HAP1/Http contributes to perinuclear late endosome
positioning. Transport to the cell periphery is mediated in association with kinesin motor
complexes (Kif3a/Kinesin-2 via FYCO1 or Kinesin-1 via SKIP). (d) Distinct multiprotein complexes regulate transport to and from late endosomes. Rab5-Rab7 conversion
involves coordinate inactivation of Rab5 and activation of Rab7, transition of CORVET
complex to HOPS complex, which ensures seamless cargo transport to late endosomes.
Handoff to ESCRT machinery enables membrane invagination and sequestration of
growth factor receptors on intraluminal vesicles of multivesicular bodies. Rab7-retromer
complex enables Golgi recycling. Rab7-HOPS complex enables late endosome-lysosome
fusion.

17	
  
	
  

On multivesicular bodies and late endosomes, Rab7 facilitates coordinate cargo sorting
and bidirectional transport on microtubules through interactions with effectors that
differentially associate with dynein or kinesin motors (Figure 5b–c). Lysosomal sorting
and perinuclear transport are mediated by the Rab7 interacting lysosomal protein (RILP)
effector. RILP interacts with components of the endosomal sorting complex required for
transport (ESCRT-II) (Vps22 and Vps36) and based on depletion studies, RILP is shown
to participate in the sorting of ubiquitinated receptors into intraluminal vesicles (28, 32).
In this manner, RILP sorts and sequesters the receptors from the cytosolic signaling
machinery and targets them for lysosomal degradation. In a tripartite complex, Rab7,
RILP, and a second effector known as oxysterol-binding protein-related protein 1 L
(ORP1L) serve to recruit a dynein/dynactin motor complex that in association with
betaIII spectrin facilitates the perinuclear transport of endosomes on microtubules (32)
(Figure 5b). Endosomal lipids such as cholesterol and phosphoinositides are critical
regulators of cargo sorting and transport on the late endosomal pathway that are
integrated through Rab7 and associated motor proteins. In particular, cholesterol sensing
is integrated with transport through the Rab7 effector ORP1L (32). When cholesterol
levels are low, ORP1L promotes the association of late endosomes with the endoplasmic
reticulum via the dissociation of minus end motor proteins. The ER protein VAPB
contributes to motor dissociation and the peripheral movement of late endosomes. Being
more peripherally localized, late endosomes are poised to receive cholesterol and other
cargo internalized through early endosomes or association with the endoplasmic
reticulum (ER). Conversely, when cholesterol levels are high, the conformation of
ORP1L is altered and perinuclear transport is favored. Interestingly, Rab7CMT2B
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mutants showed similar interaction with RILP (29) although they showed enhanced
interaction with ORP1L compared to that of the wild type (47) .
Rab7 together with the early endosomal myotubularin lipid phosphatases (MTM1) and
late endosomal myotubularin-related protein 2 (MTMR2) acts as a molecular switch
controlling the sequential synthesis and degradation of endosomal PI(3)P (49). Direct
binding of the phosphatases to the phosphatidylinositol 3-kinase complex leads to
inactivation of the myotubularins. The lipid kinase myotubularin interaction also
precludes the interaction of the activated Rab7 with the lipid kinase, illustrating the
importance of protein handoffs in phosphoinositide 3-phosphate homeostasis on late
endosomes. Together, the examples cited provide evidence for Rab7 function in
endosomal lipid homeostasis in both metabolism and signaling, the disruption of which
leads to CMT disease (50). Two Rab7 effectors participate directly in the regulation of
cargo degradation. Rabring7 (Rab7 interacting ring finger protein) functions as an E3
ligase in conjunction with the Ubc4 and Ubc5 as E2 proteins (28, 32). Functionally,
overexpression of Rabring7 increases epidermal growth factor receptor degradation and
lysosome biogenesis. The proteasome alpha-subunit XAPC7 or PSMA7 in mammals has
been found to interact specifically with Rab7 and is recruited to late multivesicular
endosomes (28). Overexpression of XAPC7 impairs late endocytic transport of EGF
receptor and hence is a negative regulator of trafficking. Together, Rabring7 and XAPC7
may coordinate the degradation of ubiquitinated growth factor receptors via a link to the
proteasomal degradation machinery though further studies are required to elucidate
mechanistic details. In addition to the described Rab7 effectors whose functional

19	
  
	
  

activities have been detailed, there are many more putative effectors whose
characterization remains to be documented.
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Figure 6: Axon viability depends on coordinated endocytic trafficking and signaling.
Nerve growth factor (NGF) binds to the TrkA receptor tyrosine kinase and stimulates
phosphorylation and internalization. Endocytosed TrkA is transported from Rab5positive early endosomes to Rab7-positive late endosomes. In peripheral neurons long
distance transport of late endosomes to the cell body is critical for growth factor
degradation and proper nuclear signaling to maintain cell viability and differentiation.
Transport occurs on microtubules through Rab7, the Rab interacting lysosomal protein
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(RILP) effector and dynactin minus-end directed motor complex. Return transport to the
synapse is mediated by Rab7 in conjunction with a plus-end directed kinesin motor,
likely KIF3a. Inset illustrates endosomal membrane protein complexes involved in Rab
conversion that allows transfer of cargo along the degradative pathway. Several
conserved multimeric protein complexes first identified in yeast are thought to aid in Rab
conversion, directed transport and fusion (RETROMER: endosome to Golgi; CORVET:
early to late endosome;HOPS: late endosome to lysosome).
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Therefore, further complexity in Rab7 mediated regulation of cargo sorting, cytoskeletal
transport, and membrane fusion will emerge through continued study.
In sum, the function of the Rab7-RILP complex in sorting and cytoskeletal transport is
best characterized and has been shown not to impair Rab7CMT2B interaction (29), while
other Rab7 effector interactions like XAPC7 await further characterization.

Rab7 at the Nexus of Endocytosis and Endosomal Signaling
Endocytosis and endosomal signaling are intricately intertwined. Endocytosis of
membrane receptors typically occurs via four major routes: macropinocytocis, clathrin
mediated endocytocis, caveolin mediated endocytocis and clathrin and caveolin
independent endocytocis. To date EGFR internalization has been studied extensively and
it is known that on binding the EGF, EGFR gets activated and recruits clathrin coat
proteins to undergo a clathrin mediated endocytocis and gets released in the cytosol
following which the clathrin coat dismantles and the cargo resides in distinct endosomes
(51). However the endocytic route adopted by the neurotrophins and TrkA receptors
remains controversial. NGF stimulation increases the association of TrkA and clathrin
with membranes as observed in both PC12 cells and dorsal root ganglion (DRG) neurons.
Complexes of activated TrkA, clathrin heavy chain and clathrin adaptor protein AP-2
have been detected (52, 53). The clathrin coated vesicles isolated from NGF stimulated
PC12 cells not only show NGF-TrkA complexes but also activated signaling mediators of
MAPK pathway (53). Apart from clathrin mediated endocytocis, internalization of NGFTrkA complex can occur through clathrin and caveolin independent routes. Recently,
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identification of Pincher that mediates caveolin independent macropinocytosis of NGFTrkA complexes shows the diverse nature of the internalization processes (54).
In a cellular context, the nature of ligand-receptor interaction, the concentration of the
ligand and the magnitude of the ligand stimulated signal deeply influence the endocytic
routes adopted by the activated receptors. During neuronal development the axons that
are exposed to a concentration gradient of a particular neurotrophin might prefer different
endocytic routes and hence form distinct signaling complexes (55).

At the late endosome, Rab7 coordinately regulates intracellular signaling through special
scaffolds, selective endosome positioning and control of growth factor receptor
trafficking. Epidermal growth factor receptor (EGF receptor) and nerve growth factor
receptor (TrkA) all depend on Rab7 for their signaling and downregulation (31). For
example, upon EGF stimulation, K-Ras is endocytosed and sorted to late endosomes
where Rab7 and the p14-MP1-p18 scaffolding proteins recruit and activate MEK-ERK
on late endosomes (56, 57). MAP kinase signaling is further regulated by Rab7
dependent late endosome positioning through dynactin such that peripheral
mislocalization results in prolonged EGF receptor activation and downstream
upregulation of ERK and p38 signaling. Retrograde endosomal signaling in neurons
involves many steps starting with internalization of ligand-receptor complex, sorting of
internalized cargo into active signaling vesicles, movement of these activated vesicles
along the microtubule network to the cell body to elicit endosomal signaling and finally
dismantling this machinery to terminate the signaling.
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Rab7 regulates endosomal signaling
Rab7 plays a crucial role in concomitant neuritogenic signaling and trafficking of
activated internalized growth factor receptors. In PC12 cells it interacts with endocytosed
nerve growth factor (NGF) receptor TrkA in a growth factor and time dependent manner.
Immediately after addition of growth factor, the NGF-TrkA complex is internalized. In
the early endosome, the NGF-TrkA complex associates with Rab5 and provides a
platform for MAPK signaling by sustaining Rap1 activation exclusively from endosomes
(58). This recruits and activates B-Raf that facilitates recruitment of other components of
the MAPK signaling module. The complex of Rap1, B-Raf, ERK1 and ERK2 localizes
on the endosomal membrane and gets retrogradely translocated towards the cell body
(Figures 6 and 7) (59). Apart from the MAPK module, components of the PI3kinase
pathway have also been detected to be associated with the Trk vesicles and inhibition of
the PI3kinase activity results in impaired NGF internalization and retrograde transport
(60). Many proteins involved in endocytosis have phosphoinositide binding domains
(FYVE, PX, PH, ENTH and FERM) (61). EEA1 is a prominent example that binds to
PI3P via the FYVE domain, is known to move along with the retrograde NGF-TrkA
complex and also interacts directly with Rab5 to sort proteins to early endosome (62).
There is agreement that the Akt pathway gets activated by the surface TrkA receptors
whereas the MAPK pathway is activated from the endosomes (63). In a nutshell, target
derived NGF binds to TrkA that gets activated by tyrosine phosphorylation at the
presynaptic terminal and gets endocytosed and trafficked along microtubules to the
neuron cell body (64). Delivery of tyrosine phosphorylated TrkA to the soma activates
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the ERK1/2 and Akt signaling pathways which effect changes in gene expression and
metabolic activity required for neuritogenesis.
The localization of two signaling mediators of the TGF-β superfamily to Rab7-positive
late endosomes (p-Smad1 and p-Smad2) is also suggested to be critical for regulation of
growth factor signaling (65). At the conclusion of signaling, Rab7 may act cooperatively
with dynamin 2 and CIN85 (cbl -interacting protein of 85 kDa) to promote the transfer of
signaling receptors from late endosomes to lysosomes for degradation (66).

In neuronal cells, the receptor tyrosine kinase, TrkA is activated by nerve growth factor
(NGF). On NGF stimulation, Rab7 interacts with TrkA as it transits through early and
late endosomes. Cells expressing Rab7T22N, which is predominantly GDP-bound,
showed prolonged ERK1/2 signaling due to impaired trafficking of activated TrkA (31,
67). Disease-causing Rab7 mutants that are constitutively activated have also been shown
to exhibit enhanced NGF-stimulated ERK1/2 signaling (68). This apparent contradictory
result can be explained by the duality of Rab7 in regulating transfer of cargo to
lysosomes and interacting with scaffold proteins.
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Figure 7: The Signaling Endosome. Signaling endosome showing the recruitment of the
MAPK signaling module and the PI3K signaling mediators alongwith the NGF-TrkA
complex. The singaling complex also interacts with dynein-dynactin complex for
retrograde movement towards the cell body.
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Phosphorylation of Rab7 in response to growth factor suggests a further layer of
regulation. Large scale proteomics analyses have identified Rab7 to be both serine and
tyrosine phosphorylated. In mouse liver extracts, Rab7 was found phosphorylated on
serine 72 within highly conserved sequence near the GTP-binding pocket (69). Rab7 was
phosphorylated in response to EGF stimulation on tyrosine 183 in the C-terminal region.
Enhanced tyrosine 183 phosphorylation of Rab7 was also associated with mutant EGF
receptor and HER2 overexpression in non–small cell lung carcinoma and mammary
epithelia, respectively (70). The functional consequences of Rab7 serine and tyrosine
phosphorylation with respect to membrane trafficking, GTP binding, and hydrolysis
remain to be established.

Role of ubiquitination in receptor downregulation
Ubiquitination of activated growth factor receptors plays a crucial role in the endosomal
sorting and lysosomal targeting to downregulate receptor levels and hence signaling.
Such ubiquitination may depend on interaction with Rab7 and the Rabring7 E3 ubiquitin
ligase. The sorting of ubiquitinated receptors into luminal vesicles of multivesicular
bodies depends on the ESCRT0, ESCRTI, ESCRTII, and ESCRTIII complexes (71).
EGF receptor and TrkA endolysosomal degradation are both ubiquitin and proteasome
dependent. The K63-linked polyubiquitin chain on activated TrkA receptors gets shuttled
by the p62 scaffolding protein, possibly in association with Rab7/XAPC7, to the
proteasome for deubiquitination prior to degradation in lysosomes (72, 73). TrkA
deubiquitination prior to lysosomal degradation may allow crucial recycling of ubiquitin
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since the ubiquitin tagging is essential for optimum interaction of activated TrkA with the
transport machinery and its delivery along the long axonal route from the tip to the cell
body.
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Figure 8: Proteasomal deubiquitination of TrkA is a prerequisite for its lysosomal
degradation. TrkA receptors upon growth factor stimulation gets internalized and
ubiquitinated. The ubiquitylated cargo is captured by the p62/SQSTM1 which shuttles it
to the proteasome for deubiquitination. Following this step the cargo proceeds to
lysosomal compartments for degradation.
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Only after TrkA reaches the cell body, the termination of signaling calls for
deubiquitination of the cargo prior to its lysosomal degradation. As illustrated, the
reversible ubiquitination is an important component of growth factor receptor
downregulation (Figure 8). The Rab7-regulated, interdependent late endocytic trafficking
and signaling pathways are indispensible for translating growth factor signals into
appropriate cell responses, misregulation of which may cause this neurodegenerative
disease (74).
In sum, Rab7, a crucial regulator of endocytosis interacts with a host of different effector
proteins to orchestrate endocytic trafficking. Although ubiquitous, Rab7 mutants
implicated in CMT2B disease affect only the peripheral neurons. This raises a question
on the putative effects of differential effector interactions with Rab7 to alter endosomal
trafficking and concomitant endosomal signaling to cause neurodegeneration.

31	
  
	
  

Overall hypothesis
Rab7 plays a pivotal role in the pathogenesis of the peripheral neuropathy Charcot-MarieTooth Type 2B disease. Based on the available literature the overall hypothesis of the
dissertation is Rab7CMT2B mutants alter trafficking of activated growth factor
receptors and spatiotemporal endosomal signaling through differential interactions
with effectors.

Specific Aims
Specific Aim 1: To biochemically characterize the modulation of endosomal signaling by
Rab7CMT2B mutants.
Specific Aim 2: To measure the impact of Rab7CMT2B mutants on the spatiotemporal
fidelity of endosomal signaling relative to late endocytic traffic regulation.
Specific Aim 3: To measure the effect of differential interaction with a Rab7 interactor
(XAPC7-proteasome subunit)
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Chapter 2: Methods

Mutagenesis and plasmid construction
Rab7 used in these studies was Canis lupus familiaris (NM_001003316) (75). GFPtagged Rab7CMT2B mutants (L129F, K157N, N161T and V162M) were constructed by
site directed mutagenesis of wild-type GFP-Rab7 in the pEGFP-C3 vector. The plasmids
were used as templates for PCR-based mutagenesis. All amino acid substitutions were
generated by a one-step reverse cyclic PCR method using the appropriate base changes in
the synthetic oligonucleotides (76). The primer sequences used for generating the mutants
were as follows:
Rab7L129F (Fwd-5’-ATTGACTTCGAAAACAGACAAGTGGC-3’,
Rev-5’-CTTGTTTCCCAACACAACGAAAGGGA-3’),
Rab7K157N (Fwd-5’AGTGCCAACGAGGCCATCAATGTGG-3’,
Rev-5’-GGTCTCGAAGTAGGGAATGTTGTTT-3’),
Rab7N161T (Fwd -5’-GCCATCACCGTGGAGCAGGCGTTCCA-3’,
Rev -5’-CTCCTTGGCACTGGTCTCGAAGTAGG-3’ and
Rab7V162M (Fwd -5’GCCATCAATATGGAGCAGGCGTTCCA-3’ and
Rev -5’-CTCCTTGGCACTGGTCTCGAAGTAGG-3’.
Mutations were confirmed by sequencing the entire Rab7 gene.
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Transient Transfection and Expression of Rab7CMT2B Mutants
Cell lines were cultured as described above and passed on consecutive days to maintain
in logarithmic growth phase immediately prior to transfection. Transfections of PC12
cells were performed using Lipofectamine 2000 (Invitrogen) according to manufacturer’s
instructions. Rab7 expression was maximal 16–24h post-transfection and experiments
were conducted during this time frame. Transfection efficiency of 35% was consistently
observed.
The level of expression of GFP-tagged Rab7 wild-type and mutant proteins in transfected
PC12 cells was 3-foldhigher than the endogenous Rab7 with transfection efficiencies of
~35% (Figure 9).

Generation of stable cell lines
Stable PC12 cell lines were established using these canine Rab7 constructs with a G418
resistance marker. The Rab7 constructs used to generate stable HeLa cells was of murine
origin, and mutagenesis was performed on Rab7 in pEGFP-C1. The constructs were
subcloned into pIRESneo2 and transfected to generate stable HeLa cell lines expressing
GFP-Rab7. The GFP-Rab7 expression in all the cell lines was similar on stimulating with
EGF in a time dependent manner (Figure10).
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Figure 9: GFP-Rab7 wild-type and Rab7CMT2B mutant proteins are uniformly
expressed in PC12 Cells 3-fold above endogenous levels. (A) Transiently transfected
PC12 cells expressing GFP, GFP‐Rab7wild-type, GFP‐Rab7L129F, GFP‐Rab7K157N,
GFP‐Rab7N161T and GFP‐Rab7V162M were lysed 16h post‐transfection and
immunoblotted for Rab7 to probe for GFP-tagged proteins as well as the endogenous
Rab7 levels. (B) Films from three independent experiments were quantified using Image
J analysis. Values of overexpressed (OE) GFP‐Rab7wt and GFP‐Rab7CMT2B mutant
protein expression were compared to endogenous (Endo.) Rab7 levels. Error bars
indicating mean ±S.E.M. n=3, *p<0.05; **p<0.01.
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Figure 10: Similar levels of GFP-Rab7 expressed in all samples stably expressing
Rab7 wild-type and CMT2B mutants. Samples from EGFR degradation assays were
probed with antibody directed against GFP to assess the GFP-Rab7 expression levels for
all the samples.
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NGF stimulation protocol
NGF (200ng/ml) stimulation was performed as described previously (67).
For all NGF stimulations, a concentration of 200ng/ml of recombinant human NGF was
used. Eighteen hours post transfection, PC12 cells were washed and stimulated with NGF
for 10min in serum-free medium (DMEM and 0.1% BSA) to drive internalization of
TrkA into endosomes. Subsequently, PC12 cells loaded with internalized activated TrkA
bound to NGF (77) were chilled on ice to arrest endosomal trafficking, and the remaining
surface bound NGF was removed by three washes with ice-cold “surface strip buffer”
(0.2 M acetic acid and 0.5 M NaCl) (78), followed by three washes with ice-cold PBS.
Afterward, cells were reincubated for the indicated time points in pre-warmed serum-free
medium and subsequently processed for immunofluorescence or biochemical assays.

EGFR Degradation Assays
For degradation assays, stable HeLa, stable PC12 cells and A431 cells grown on six well
plates were serum starved for 5h in DMEM with 25µg/ml cycloheximide and stimulated
with serum free media containing 100ng/ml epidermal growth factor (EGF;Invitrogen)
and 25µg/ml cycloheximide. At time points (0–4h), cells were lysed with 80µl SDS lysis
buffer (10mM Tris, pH 7.5, 140mM NaCl, 1% [w/v] SDS, 5mM EDTA, 2mM EGTA,
1mM PMSF, 1mM Na3VO4,10mM NaF, 30mM sodium β-glycerophosphate and protease
inhibitor cocktail CLAP: 10µg/ml of chymostatin, leupeptin, antipain, and pepstatin A)
and brief sonication to shear DNA. Cellular debris was removed by centrifugation, and
total protein concentration was quantified using a BCA protein assay (Pierce,Rockford,
IL). For siRNA knockdown experiments a previously reported protocol for endogenous
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Rab7 ablation was followed human Rab7 siRNA (Gene ID 7879) was purchased from
Dharmacon Technologies (38).

Immunoprecipitation
BHK-21 cells were grown on 100-mm dishes and GFP-Rab7 wild-type or individual
CMT2B mutants were co-transfected with XAPC7-DsRed plasmid using Lipofectamine
2000 (Invitrogen). Mock transfections were performed using a suitable vector lacking an
insert. Cell homogenates were prepared in homogenization buffer (HB, 20mMhepes, pH
7.4 and 2mM CaCl2) buffer by passage through a 27-gauge needle 10-20 times. Nuclei,
cell debris and large organelles were removed by low speed centrifugation at 1000 rpm
for 5min in an Eppendorf microcentrifuge at 4ºC. Mitochondria were removed by
centrifugation at 1,950g for 20min, and a crude membrane fraction was collected by
centrifugation at 105,000 g for 2h. The pellet was resuspended in RIPA buffer (1% (v/v)
Nonidet P-40, 0.5% (w/v) deoxycholate, 0.1% (w/v) SDS, 50mM Tris pH 7.4, and
150mM NaCl) containing a protease inhibitor cocktail (1mM phenylmethylsulfonyl
fluoride, 1mM benzamidine, 1µg/ml CLAP) and immunoprecipitation of XAPC7 was
performed using polyclonal rabbit anti-Rab7 as described (79-81). Immunoprecipitates
were recovered with Protein A-Sepharose (Sigma-Aldrich) and resolved on 12% gels and
transferred to hybond-C membrane (Amersham Biosciences). Immunoblot analysis was
performed with a mAb directed against XAPC7 or with our rabbit polyclonal antibody
directed against Rab7 (NW112) (82).
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Gel electrophoresis and Immunoblot Analyses
Samples were resolved by SDSPAGE on 8% gels for EGFR degradation assays and 12%
gels for p38 and ERK1/2, transferred to nitrocellulose, blocked with 3% newborn calf
serum in Tris Buffer Saline Tween-20 (pH-8). Samples comparing wild-type and mutant
lysates were resolved on a single gel for each experiment. Actin, phospho-proteins, total
p38 and ERK1/2 were analyzed on a single blot.

Fluorescence Recovery after Photobleaching (FRAP) Assay
BHK-21 cells were seeded and grown to 50-60% confluency on coverslips. GFP-tagged
wild-type Rab7, dominant negative Rab7T22N, constitutively active Rab7Q67L and
individual CMT2B mutants were overexpressed in BHK-21 cells using transient
transfection. FRAP experiments to monitor GTPase activation were performed based on
published procedures at 37°C and using cells on glass coverslips mounted in a chamber
suited for inverted microscopic imaging (83). Live cell images were collected using a
BioRad Radiance 2100 mounted on a Nikon TE2000 inverted microscope. A subset of
GFP-Rab7 vesicles were bleached for 10s by a high-intensity light illumination at 488
nm, and the fluorescence recovery in the bleached spot was quantified. Fluorescence
recovery was measured every 20s for a total of 600s for each sample. The FRAP
measurements were performed on n=30 cells for each Rab7 mutant and repeated a total of
n=3. FRAP measurements were made both near the nucleus as well as on peripheral
vesicles with no significant differences. The recovery curves were corrected for loss of
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total fluorescence due to bleaching induced by repeated imaging on a control area
without GFP-Rab7 decorated endosomes.

Immunofluorescence Microscopy
Cells transfected with GFP-tagged Rab7 wild-type and CMT2B mutant plasmids were
starved for 14h and incubated with Alexa555-tagged EGF for 1h at 4°C. Cells were kept
at 37°C for 10min followed by wash in DMEM and reincubated at 37°C for 20, 60, and
120min. Cells were fixed with 3% paraformaldehyde and permeabilized for 5min in 0.1%
(v/v) Triton X-100. Blocking and antibody incubations included 0.4% fish skin gelatin
(Sigma-Aldrich). Coverslips were viewed on a Zeiss LSM 510 confocal microscope
using plan-Neofluor 40X/1.30 oil or plan-Neofluor 63X/1.30 numerical aperture oil
objectives, taking 0.4-µm optical sections. All images were exported as tiff files and
compiled in Adobe Photoshop (San Jose, CA). For comparative analyses, cells were
imaged under identical parameters, and fluorescence intensity was analyzed using
Slidebook 4.1 software (Intelligent Imaging Innovations, Denver, CO). The percentage of
colocalization was analyzed using Slidebook 4.1 software. Masks were created for each
channel for all of the z-stacks acquired for each image, and the overlap was assessed with
AND functions to determine the percentage of colocalization of the two channels.

Subcellular Fractionation
Nuclear and cytosolic fractions were prepared as previously described with minor
modifications (84). PC12 cells and HeLa cells stably expressing GFP-Rab7CMT2B
mutants were plated on 60mm dishes. For NGF stimulated cells were transiently
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transfected with GFP-tagged Rab7CMT2B mutants. To separate the nuclear and cytosolic
pools of ERK1/2, the cells were serum starved for 5h and stimulated with NGF for 10min
followed by surface stripping of the ligand. The cells were then incubated in starvation
medium (DMEM containing 0.1% BSA) for 2h, 6h or 24h at 37°C. The cells were
washed thrice in ice cold PBS and scraped in 750µl of lysis buffer (10mM Tris-HCl, pH
7.4, 10mM NaCl, 3mM MgCl2 0.3% (v/v) NP-40, 1mM PMSF, 1mM Na3VO4,10mM
NaF, 30mM sodium β-glycerophosphate, 10mg/ml chymostatin, 10mg/ml leupeptin,
10mg/ml antipain and 10mg/ml pepstatin). Cells were incubated on ice for 5min followed
by centrifugation at 500g for 5min to pellet the nuclei. The remaining supernatant was
taken as the cytosolic fraction. Nuclear pellets were washed in the same lysis buffer
without NP-40. The cytosolic and nuclear fractions were boiled in 2X Laemmli sample
buffer and resolved on 10% SDS polyacrylamide gels and probed with a phospho
ERK1/2 antibody. The purity of the nuclear fraction was verified with an antibody
directed against nuclear lamin B.

Expression and purification of GST-RILP.
Competent E.coli BL21 cells were transformed with a plasmid encoding GST-RILP.
Cultures were grown at 37°C to an absorbance of 0.5O.D. measured at 595 nm and
protein expression induced by transfer to room temperature and addition of 0.2mM
isopropyl-beta-D-1-thiogalactopyranoside (IPTG) for 16-18h to maximize the yield of
properly folded active fusion protein. Purification of GST-RILP was performed
according to standard procedures as previously described (85, 86). The harvested
bacterial cell pellet was resuspended in phosphate buffer saline. Cells were lysed using
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lysozyme and microtip sonicator (Misonix Inc., Newtown, CT, U.S.A.).The samples were
kept on ice. The power setting was kept at 50% with intermittent pulse of 5s repeated
twice with a gap of 30s in between. The cell lysates were mixed with 10% TritonX-100
end over end for 30min at 4°C. Cells were then centrifuged at 8,000g for 10min to pellet
the cellular debris. The supernatant was mixed with glutathione Sepharose 4B slurry and
bound at 4°C for 2h using gentle agitation to keep the resin suspended in the lysate
solution. Glutathione sepharose 4B beads with bound protein was settled using low speed
centrifugation (500g) followed by multiple washes before eluting the glutathione
Sepharose 4B bound GST-tagged protein with 10mM Glutathione in 50mM Tris-HCl
elution buffer. Eluted protein was concentrated by passing through Millipore Amplicon
Ultra Tubes (MWCO 30,000). The purified protein was quantified using the BCA protein
estimation kit (Pierce). Single use aliquots stored at -80ºC were used in experiments.

Stimulation, cell lysis and flow cytometry analysis of active GTPases by effector beads
HeLa cells were plated in 48-well plates and incubated overnight at 37°C with 5% CO2
and 90% humidity. Cells were starved for overnight in serum-free medium followed by
stimulation with EGF at 100 ng/ml and inhibitor concentration at 10µM. After incubating
cells for desired time points, cells were lysed with 100µL ice-cold RIPA buffer. The
plates are scraped, and the lysate collected. For the purposes of standardization, a fraction
of the supernatant was collected, quantified using BCA protein estimation kit (Pierce).
Lysates were kept ice cold at all times to limit hydrolysis of active GTPases. Lysates
were sonicated briefly, and then centrifuged at 14,000rpm in Eppendorf mirocentrifuge
for 10min to clear the lysate of debris and DNA. 10,000 beads for each effector assay
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were used and added to a lysate. The beads were synthesized as described earlier (87). If
probing for more than one protein, the lysate was divided into desired tubes and probed
individually. The beads and lysate were allowed to incubate for 1h at 4°C.

After

incubation, the beads were pelleted in a cold centrifuge. The bead pellets were
resuspended in RIPA buffer and incubated with a primary monoclonal antibody for the
target GTPase, with gentle shaking for 1h.

The beads were than centrifuged and

resuspended in RIPA buffer with an Alexa 488 secondary antibody at a 1:200 dilution for
1h with shaking at 4°C. Finally the beads were centrifuged once and resuspended in
100µL RIPA buffer for quantification in the flow cytometer. The assay concept is
illustrated below (Figure 11).
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Figure 11: Flow cytometry based assay to determine Rab7-RILP interaction.
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Chapter 3: Results- Rab7CMT2B mutants alter endocytic trafficking

It may be postulated that the process of maturation of the internalized cargo from early
endosome to late endosome or from late endosome to lysosome is delayed under diseased
conditions. Previous studies have indicated misregulation of intracellular trafficking
cause defects in axonal transport and hence impair supply and clearance. This slowed
axonal transport gradually leads to progressive neuronal cell death (93). Neurons
expressing mutant form of mitofusin found in Charcot-Marie-Tooth Type 2A (CMT2A)
dramatically hampers the mitochondrial mobility resulting in their redistribution in the
soma and proximal axon (94). This leads to redistributed mitochondria that directly
impact the aerobic respiration (i.e. generation of ATP) and calcium buffering. Hence a
neuron might eventually die due to starvation. Studying the intracellular trafficking and
hence its impact on endosomal signaling is key in determining the pathogenesis of
CMT2B disease.

Rab7CMT2B mutants show perinuclear distribution
As shown in Figure 12, all of the CMT2B associated Rab7 mutants were observed to
accumulate with a perinuclear distribution consistent with localization to endosomes.
HeLa cells were transiently transfected with GFP-tagged Rab7 wild-type and CMT2B
mutants and analyzed for their subcellular distribution by confocal microscopy.
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Figure 12: Rab7CMT2B mutants show a perinuclear distribution consistent with
localization to endosomal membranes.
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Rab7 Mutants Display Altered Membrane Association Kinetics
Rab7, like other Rab GTPases, exists in an active, GTP-bound state that is membranebound and an inactive, GDP-bound state that is cytosolic. To investigate the membrane
association and cytosolic cycling of the Rab7CMT2B mutants, BHK-21 cells were
transiently transfected with
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Figure 13: Rab7CMT2B mutants show differential membrane cycling. BHK-21 cells
transfected with GFP-Rab7 wild-type (WT) and CMT2B mutants were used for
Fluorescence Recovery After Photo bleaching (FRAP) studies. Regions of transfected
cells were photobleached with a high intensity laser and recovery of fluorescence tracked
over time. Representative time lapse images of GFP-Rab7 vesicles before and after
photobleaching are shown. At least 30 cells were analyzed for each cell condition in each
trial and results are representative of three independent experiments.
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GFP-tagged wild-type Rab7 and CMT2B mutants, and FRAP analyses were conducted as
described previously (83). Regions of the transfected cell were photobleached by high
intensity laser, and the recovery of fluorescence was tracked over time (Figure 13). The
time of recovery of 50% of the fluorescence measured for Rab7 wild-type (t1/2=40.6 s)
was comparable with published literature (t1/2= 52 s). Three of the Rab7CMT2B mutants
showed a slower rate of fluorescence recovery compared with wild-type Rab7 (Figure 14
and Table 2).

The L129F and V162M showed similarly slow recoveries compared with the wild-type
(t1/2=134.3 s and t1/2=127.6 s). Our finding is consistent with a previous report (83),
although recovery rates for the two mutants were not explicitly stated. Among the
previously untested mutants, K157N also showed a dramatically decreased fluorescence
recovery (t1/2 =130.7 s), whereas the half-time of fluorescence recovery of N161T (57.7
s) was similar to that of the wild type (40.6 s). As expected, the predominantly GDPbound, cytosolic dominant negative Rab7T22N mutant showed little or no fluorescence
recovery.
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Figure 14: Quantitative analysis of differential membrane cycling of Rab7CMT2B
mutants. FRAP analyses show a decreased rate of fluorescence recovery of all the
Rab7CMT2B mutants compared to the wild-type. Rab7T22N mutant showed little or no
fluorescence recovery. The differences in fluorescence recovery from three independent
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trials and 30 cells per trial are plotted ± S.E.M. Asterisks denote p<0.05 based on oneway ANOVA with Dunnett’s post-test and relative to Rab7 wild-type control.
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The differences were statistically significant for Rab7V162M and Rab7L129F, in
agreement with previous studies (47), and also for the previously untested Rab7K157N
and dominant negative Rab7T22N mutants. The slower recovery rates are indicative of
increased membrane residence times for three of the four Rab7CMT2B mutants, which
would be expected to impact endocytic trafficking.
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Table 2: FRAP measurements of Rab7 wild-type and other mutants
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The Rab7CMT2B mutants interact with TrkA
The interaction of Rab7 with the receptor tyrosine kinase, TrkA is NGF dependent and
furthermore the association is time dependent following nerve growth factor (NGF)
stimulation (67). To study the impact of the CMT2B associated Rab7 mutants on TrkA
interaction, the GFP-tagged versions of Rab7 bearing L129F, K157N, N161T and
V162M substitutions were generated.
Based on previous studies, GFP-Rab7 fusion proteins preserve the functional properties
of the untagged proteins (89). To see if the disease Rab7CMT2B mutants impair
interaction with TrkA on NGF stimulation a set of co-immunoprecipitation assays were
done.
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In agreement with the published literature (67), endogenous Rab7 was found to
coimmunoprecipitate with TrkA following NGF stimulation and the maximum
interaction occurred 1h after stimulation (Figure 15).
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Figure 15: Rab7 interacts with TrkA in a time dependent manner. PC12 cells were
stimulated with NGF (200ng/ml) for 15-60min as indicated.

Cells were lysed and

samples of cell lysates were immunoblotted for TrkA and Rab7 as a measure of degree of
protein-protein interaction. Lysate samples containing equal amounts of protein were
immunoprecipitated (IP) with a pAb directed against Rab7 and immunoblotted for TrkA.
Subsequently, the membrane was stripped and re-blotted for Rab7.
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Therefore, 1h NGF stimulation was used to test for an interaction between TrkA and
GFP-tagged wild-type Rab7 as well as the CMT2B GFP-Rab7 mutants. GFP-tagged
wild-type Rab7 and the Rab7CMT2B mutants were all seen to co-immunoprecipitate
with TrkA at similar levels (Figure 16), indicating that the mutant proteins were not
impaired in their ability to bind to TrkA receptor.
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Figure 16: Rab7CMT2B mutants interact with TrkA on NGF stimulation. PC12
cells were transfected with GFP-tagged Rab7CMT2B disease mutants and stimulated
with NGF for 60min. Equal amounts of lysate samples were immunoprecipitated with
antibodies against GFP to precipitate the GFP-tagged Rab7
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and subsequently immunoblotted for TrkA. The membrane stripped and reprobed with
antibodies against GFP.
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Rab7CMT2B Mutants Delay TrkA Degradation
The effect of the Rab7CMT2B mutants on endocytosis and transport of EGFR was
monitored in PC12 cells stably expressing GFP tagged wild-type Rab7 and CMT2B
mutants. Cells were serum-starved and NGF-stimulated, and TrkA degradation was
traced over time as a measure of transport to lysosomes (Figure 17). The inclusion of
cycloheximide precluded further synthesis of EGFR upon stimulation.
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Figure 17: Rab7CMT2B mutants delay TrkA degradation. PC12 cells stably
expressing GFP-tagged Rab7 wild-type and CMT2B mutants were serum starved, treated
with cycloheximide for 30min and stimulated with 100ng/ml NGF for the indicated time
points. Cells were lysed and probed with anti TrkA antibody.
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The cells expressing GFP-Rab7 wild-type showed complete degradation of TrkA around
90min post NGF stimulation whereas the cells expressing the disease mutants showed a
delay in degradation. The amount of undegraded TrkA present at 120min was in the order
N161T>L129F>K157N>V162M>WT.
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Rab7CMT2B Mutants Delay EGFR Degradation

The effects of the Rab7CMT2B mutants on endocytosis and transport of EGFR were
monitored in HeLa cells and PC12 cells stably expressing GFP-tagged wild-type Rab7
and CMT2B mutants. Cells were serum-starved and EGF-stimulated, and EGFR
degradation was traced over time as a measure of transport to lysosomes. The inclusion
of cycloheximide precluded further synthesis of EGFR upon stimulation. The levels of
EGFR at 15min post-stimulation were considered to be 100%, and subsequent levels at
each time point were calculated accordingly. Expression of all Rab7CMT2B mutants
kinetically delayed EGFR degradation in HeLa cells compared with the wild-type control
(Figure 18 A-D).
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Figure 18: Rab7CMT2B mutants delay EGFR degradation. (A) HeLa cells stably
transfected with GFP-tagged wild-type (WT) Rab7 and CMT2B disease mutants were
starved in DMEM for 5h and pretreated with cycloheximide for 1h followed by EGF
stimulation (100ng/ml) in a time dependent manner as indicated. Representative blots
from one of three independent experiments are shown. Subsequently, cells were lysed
and equal amounts of protein were immunoblotted and probed for EGFR with actin as the
loading control. (B) Films from three independent experiments were quantified by Image
J analysis. Line graphs show levels of undegraded EGFR in GFP-WT Rab7 and CMT2B
mutant expressing cells. In each case the amount of EGFR was normalized to the amount
of actin. (C) Neuronal PC12 cells stably transfected with GFP-tagged wild-type (WT)
Rab7 and CMT2B disease mutants were starved in DMEM for 5h and pretreated with
cycloheximide for 1h followed by EGF stimulation (100ng/ml) in a time dependent
manner as indicated. Representative blots from one of three independent experiments are
shown. Subsequently, cells were lysed and equal amounts of protein were immunoblotted
and probed for EGFR with actin as the loading control. (D) Films from at least three
independent experiments were quantified by Image J analysis. Line graphs show levels of
undegraded EGFR in GFP-WT Rab7 and CMT2B mutant expressing cells. In each case
the

amount

of

EGFR

was

normalized
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the

amount

of

actin.

Rab7N161T mutant-expressing cells showed the slowest EGFR degradation kinetics,
whereas the Rab7V162M mutant exhibited the fastest degradation kinetics among the
mutants.
The levels of overexpressed GFP-Rab7 were similar in all of the cell lines under the
given experimental conditions (Figure 10). To confirm the results in additional cell lines,
we tested the effects of Rab7CMT2B mutants on EGFR degradation in stable PC12 cells
(Figure 18 C and D) and transiently transfected A431 keratinocytes (Figure 19 A and
B). A delay in EGFR degradation was found in both cell types overexpressing the
Rab7CMT2B mutants. The K157N, N161T, and L129F mutants showed significantly
delayed EGFR degradation rates compared to wild-type, with the V162M mutant
exhibiting degradation rates most similar to wild-type (Figure 18D). The cumulative data
strongly suggest that the disease mutants impair endosomal trafficking and degradation of
EGFR and that the effect is not a cell type specific while also observed in a cell model
commonly used for studying neuronal differentiation.
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Figure 19: Rab7CMT2B mutants delay EGFR degradation in A431 cells. (A) A431
cells transfected with GFP-tagged Rab7 wild-type and CMT2B mutants were starved for
5h and pretreated with cycloheximide and stimulated with EGF for 1h and 4h. A431 cell
lysates were collected at the indicated time points as described in experimental
procedures. Samples were resolved by SDS-PAGE and then subjected to immunoblotting
to detect EGFR and actin. Same samples were resolved by 12% SDS-gel to detect GFP
Rab7 expression using rabbit polyclonal GFP antibody as shown at the bottom of the
each box. (B) EGFR levels were quantified densitometrically and normalized to actin.
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The milder impairment in EGFR trafficking caused by the disease mutants in the HeLa
cells relative to PC12 cells or A431 keratinocytes might be attributed to differences in
EGFR levels or the presence of endogenous wild-type Rab7 that can still serve to
facilitate normal endocytic trafficking in the cells stably overexpressing the Rab7CMT2B
mutants.
Coexpression of mutant allele and wild-type alleles is the expected genotype in
autosomal dominant CMT2B. Nevertheless, to further confirm that the slowed EGFR
transport and degradation were directly attributable to the Rab7CMT2B mutants.
Therefore, HeLa cells overexpressing mutant GFP-tagged Rab7N161T protein of murine
origin were treated with siRNA to specifically deplete the endogenous human wild-type
Rab7 or with a scrambled.

69	
  
	
  

Figure 20: Knockdown of endogenous wild-type Rab7 showed a pronounced delay
in EGFR degradation of Rab7N161T mutant compared to Rab7 wild-type. (A) HeLa
cells stably expressing murine GFP-Rab7 wild-type (WT) and CMT2B mutants were
transfected with scrambled siRNA (scr) and siRNA targeted against human Rab7a
(siRab7) to knockdown the endogenous Rab7. Cells were kept for 48h to bring about
effective knockdown. Representative western blot is shown showing the unaltered
expression of murine GFP-Rab7 (~50kDa) and knockdown of endogenous Rab7
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(~25kDa). (B) Densitometric quantification of the western blots showed ~50%
knockdown of endogenous Rab7 in both GFP-Rab7 wild-type and N161T expressing
cells. (C) HeLa cells stably expressing murine GFP-Rab7 wild-type and CMT2B mutants
were transfected with siRNA targeted against endogenous Rab7. The cells were
incubated for 48h following transfection to bring about effective knockdown of
endogenous Rab7 following which cells were starved for 5h and pretreated with
cycloheximide for 1h and stimulated with EGF for the indicated time points. Rab7
N161T showed a pronounced delay in EGFR degradation compared to the wild-type. (D)
Densitometric quantitation of films from at least three independent experiments showed a
faster kinetics of EGFR degradation in cells expressing wild–type Rab7 compared to
those expressing Rab7N161T.
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Knockdown of endogenous human Rab7 in cells overexpressing Rab7N161T showed a
more pronounced delay in EGFR degradation than was seen in the presence of
endogenous wild-type Rab7 protein (Figure 20 C and D). It was somewhat surprising
that there was also a mild slowdown of EGFR degradation in the cells where endogenous
Rab7 was depleted but GFP-tagged Rab7 wild-type protein was overexpressed,
suggesting that the GFP tag may have a mild effect on protein function, as has been noted
for Arf GTPases (90).
Overall, the siRNA data support the conclusion that the Rab7CMT2B mutants directly
impair the trafficking and degradation of EGFR.

Rab7CMT2B Mutants Slow Endocytic Transport of EGF
To assess the stage where growth factor transport was being delayed by the Rab7CMT2B
mutants, we tracked the time-dependent transit of internalized EGF from the early
endosome to late endosomes/lysosomes. HeLa cells were transiently transfected with
GFP-tagged Rab7 wild- type or CMT2B mutants.
Post-transfection, cells were serum-starved and stimulated with Alexa555-labeled EGF
for 10min, followed by washing and reincubation in serum-free medium for 20 or 60min,
respectively. At the 20min time point, internalized EGF was significantly associated with
EEA1-positive early endosomes in the Rab7CMT2B mutant cells seen as purple punctate
structures in the merged images (Figure 21A).
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Figure 21: Rab7CMT2B mutants show a delay in EGF transport from early to late
endosomes. HeLa cells transfected with GFP-tagged wild-type (WT) Rab7 and
Rab7CMT2B mutants were starved for 14h and stimulated with Alexa555-tagged EGF
for 10min followed by reincubation in DMEM for 20min and 60min (A, B) at 37ºC,
permeabilized with Triton X-100 and stained with anti-EEA-1 antibody. (C) Bar graphs
showing the degree of colocalization of EGF and EEA-1 at 20min and 60min. At least 30
cells were scored for each construct of one experiment for a total of three independent
experiments. The degree of colocalization of EGF with EEA-1 was analyzed by
Slidebook 4.1 software and the differences are represented as ± S.E.M. Scale Bar =10µm.
(D) Bar graphs showing the degree of colocalization of EGF and Lamp1 at 60min and
120min. At least 30 cells were scored for each construct of one experiment for a total of
three independent experiments. The degree of colocalization of EGF with Lamp1 was
analyzed by Slidebook 4.1 software and the differences are represented as ± S.E.M.
Values in all cases are from three independent experiments plotted ± S.E.M. Asterisks
denote p<0.05 based on one-way ANOVA with Dunnett’s post-test and relative to Rab7
wild-type control.
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Quantitative analyses of the degree of colocalization of EGF with EEA1 at 20min post
stimulation were essentially identical in cells expressing wildtype and mutant proteins,
suggesting no impairment in internalization or delivery to early endosomes. However, the
degree of colocalization of EEA1 and EGF was significantly higher in the Rab7CMT2B
mutants at the longer time point (60min) compared with the wild-type Rab7 cells, as can
be seen from more purple punctuate structures in the Rab7N161T mutant compared with
the wild-type (Figure 21B and C). The Rab7K157N mutant exhibited the greatest
retention and accumulation of EGF in the EEA1-positive early endosomes, followed by
V162M, N161T, and L129F. The data indicate a delay in the transit of the internalized
EGF from early to late endosomes when the Rab7CMT2B mutant proteins are expressed.
The transport of internalized EGF to late endosomes/lysosomes was measured by
stimulating with Alexa555-labeled EGF for 10min, followed by washing and
reincubation in serum-free medium for 1–3h and staining for Lamp1-positive structures.
Quantitative analyses at two time points showed a marginally higher degree of
colocalization of EGF and Lamp1 in cells expressing wild-type Rab7 compared with the
disease mutants (Figure 21D). This is consistent with the protracted localization of EGF
in EEA1-positive early endosomes. At a longer time point (3h), the Rab7CMT2B mutants
showed a higher degree of colocalization of EGF and Lamp1, consistent with a kinetic
delay in progressing to lysosomal degradation. It is worth noting that the difference in the
degree of colocalization between the wild-type and Rab7CMT2B mutants is about 10–
15% and is statistically significant.

75	
  
	
  

These data further support a delayed trafficking of EGF and its associated receptor to late
endocytic compartments in the Rab7CMT2B mutant-expressing cells compared to the
wild type.
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Chapter 4: Results-Rab7CMT2B mutants alter endosomal signaling
Endocytosis and cell signaling are interdependent and bidirectionally linked cellular
processes. These intertwined processes influence cell motility and cell fate determination
(91, 92). Cells respond to external stimuli by activation of signaling receptors which get
endocytosed and sorted into distinct endosomal compartments. Endocytosis regulates the
availability of a number of receptors available for stimulation at the plasma membrane
and the endocytosed ligand stimulated receptors activates downstream mediators that in
turn regulate the process of endocytocis. Endosomes serve as decision forks involved in
recycling, secretion and degradation that determines the receptor level and activity.
Endosomes have the unique feature to serve as signaling scaffolds during signal
transduction. The small volume of endosomes allows for optimum interaction of ligand
with receptor and the slow process of sorting facilitates longer duration of signaling.
Impaired trafficking of activated growth factor receptors would be expected to alter
endosomal signaling through differential interaction with effectors.
Rab7CMT2B mutants are gain of function mutations (88) hence would be expected to
interact with TrkA on NGF stimulation. On activation with NGF, TrkA would be
expected to undergo phosphorylation and activate the downstream signaling pathways to
upregulate the differentiation genes. It may be postulated that the disease mutants would
differentially activate the downstream mediators of activated TrkA receptors.
Previous studies have shown that Rab7 interacts with TrkA in a nerve growth factor
(NGF) and time dependent manner. Overexpressing the Rab7T22N dominant negative
mutant that is predominantly GDP-bound was shown to prolong ERK1/2 signaling and
stimulate neurite outgrowth. Under diseased conditions, Rab7 would be expected to
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impair trafficking of activated growth factor cargos. As such disease mutants would
expect to alter the endosomal signaling of activated TrkA receptors. Hence it is
postulated that Rab7CMT2B mutants alter the subcellular partitioning of activated
mediators of Trk signaling.

It was observed that Rab7CMT2B mutants delay the trafficking of activated, internalized
EGFR. This would increase the membrane residence time of the signaling endosomes. As
such activation of EGFR and its downstream signaling mediators like ERK1/2 would be
expected to be enhanced and account for differential activation of endosomal signaling.
The ligand induced stimulation of EGFR leads to activation of MAPK signaling scaffold
that gets recruited on the activated, internalized cargo. Thus the appropriate trafficking of
activated EGFR to endosomes controls the spatio-temporal regulation of MAPK
signaling. Typically the activated ERK1/2 gets translocated to the nucleus and activate
Elk-1 transcription factor. However the activation of Elk-1 in the CMT2B mutants may
be impaired and the positioning of the signaling endosomes might be critical in
determining the outcome of nuclear signaling i.e. enhanced Elk-1 or reduced Elk-1
activation (Figure 22).

78	
  
	
  

Figure 22: Intracellular positioning of signaling endosomes determine the signal
output. Distribution of endosomal system in wild type (perinuclear), Rab7Q67L
overexpressed (perinuclear and clustered) and p50 overexpressed cells (peripheral) and
altered ERK and nuclear signaling in the different systems.
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Rab7CMT2B mutants show differential TrkA and EGFR phosphorylation following
growth factor stimulation
Rab7 is known to control endosomal trafficking of TrkA as well as receptor signaling. To
assess the effect of the Rab7CMT2B mutants on NGF signaling, PC12 cells expressing
the mutant proteins were briefly stimulated with NGF followed by removal of residual
surface bound NGF (‘surface stripping of ligand’ as described in Materials and Methods)
to maximize detection of signaling from activated, internalized TrkA receptors over the
course of 2–24h.higher phospho-TrkA levels were consistently observed across multiple
time points in cells expressing the GFP-tagged Rab7CMT2B mutants as compared to
GFP-Rab7 wild-type or GFP only expressing control cells (Figure 23). Expression levels
of all GFP proteins were constant at all time points. Quantification of replicate
experiments showed that Rab7L129F, Rab7K157N, Rab7N161T and Rab7V162M
expressing cells had 2.1–3.9 fold higher levels of phospho-TrkA than the GFP only
expressing control cells and 1.3–1.8 fold higher levels than the GFP-Rab7 wild-type
expressing cells at the 2h and 6h time points (Figure 23B, numerical values are
provided in Table 3). At the 24h time points, the pTrkA signal was greatly diminished
and the differences between the mutants and the controls were no longer statistically
significant. There was no down regulation of total TrkA levels in the lysates, similar to
previous reports where Rab7 dominant negative mutant was expressed (67).
Nevertheless, the higher TrkA phosphorylation is suggestive of differential interaction of
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the Rab7 mutants with signaling complexes that leads to an increase in activated TrkA
receptors in endosomes.
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Figure 23: Cells expressing Rab7CMT2B mutants exhibit higher levels of phosphoTrkA following NGF stimulation. (A) Transiently transfected PC12 cells expressing
GFP, GFP-Rab7 wild-type, GFP-Rab7L129F, GFP-Rab7K157N, GFP-Rab7N161T,
GFP-Rab7V162M were briefly stimulated with NGF (200ng/ml) followed by surface
stripping of ligand and reincubation in 0.1% BSA-DMEM for 2h,6h and 24h
respectively. Subsequently, cells were lysed and equal amounts of protein were
immunoblotted and probed for total and phosphorylated TrkA. Significantly, higher
levels of phosphorylated TrkA were found at 2h and 6h. Equal amounts of protein from
cell lysates were probed with antibodies against GFP. GFP-Rab7 wild-type and GFPRab7CMT2B mutant proteins are uniformly expressed in PC12 cells under these
conditions as shown in the adjacent representative blot. (B) Films from four independent
experiments were quantified by Image J analysis. Bar graphs show pTrkA in GFP-Rab7
wild-type and CMT2B mutant expressing cells. In each case the amount of pTrkA was
normalized to the amount of GFP protein expressed. The bar graph shows the foldchange in pTrkA as a function of pTrkA in the GFP only control at each respective time
point. Error bars indicating mean ± S.E.M., n=4, **p<0.01, ***p<0.001.
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Table 3. Fold-changes in phospho-TrkA and phospho-ERK1/2 due to
Rab7CMT2B mutants.
Expressed
Protein

GFP
GFP-Rab7
wt

Phospho-TrkA
Fold change relative to
GFP

Phospho-TrkA
Fold change relative to
GFP-Rab7wt

Phospho-ERK1/2
Fold change relative to
GFP

Phospho-ERK1/2
Fold change relative to
GFP-Rab7wt

2h
1.0

2h

6h

24h

2h
1.0

2h

6h

24h

1.0

1.0

1.0

1.0

1.0

1.0

6h
1.0

24h
1.0

6h
1.0

24h
1.0

GFPL129F

3.1
p<0.001

2.72
p<0.01

1.34
p<0.05

1.48
p<0.05

2.58
p<0.001

2.15
p<0.01

2.67
p<0.05

1.62
p<0.01

1.75
p<0.01

2.17
p<0.05

GFPK157N

3.57
p<0.001

2.14
p<0.001

1.53
p<0.01

1.52
p<0.05

2.49
p<0.001

2.14
p<0.001

2.84
p<0.05

1.57
p<0.001

1.74
p<0.01

2.3
p<0.05

GFPN161T

4.39
p<0.001

2.9
p<0.001

1.88
p<0.001

1.58
p<0.01

2.98
p<0.001

1.82
p<0.01

2.54
p<0.05

1.87
p<0.01

1.48
p<0.01

2.06
p<0.05

GFPV162M

3.96
p<0.001

3.37
p<0.001

1.70
p<0.001

1.83
p<0.001

3.14
p<0.001

2.6
p<0.001

2.65
p<0.05

1.97
p<0.001

2.12
p<0.001

2.15
p<0.05

Data from 4 independent experiments measuring TrkA phosphorylation and 3 independent
experiments assessing ERK1/2 phosphorylation were evaluated using unpaired, one-tailed
Student’s t-test.
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Changes in the activation status of the EGFR in the context of Rab7CMT2B mutants
were assessed by probing the time-dependent phosphorylation. A phospho-EGFR
antibody relative to cells expressing wild-type Rab7 directed against the tyrosine 1045
residue that is phosphorylated on EGF stimulation was used to monitor changes in the
status of phosphorylation. The levels of phosphorylated EGFR were normalized to the
levels of total actin. The Rab7CMT2B mutants showed 2–3-fold higher levels of
phosphorylated EGFR within 15min of EGF stimulation compared with the wild-type
(Figure 24 A and B). The Rab7N161T mutant showed the highest level of EGFR
phosphorylation followed by V162M, L129F and K157N. The rate of dephosphorylation
of EGFR measured over 240min was found to be up to 3-fold slower in the disease
mutants WT > K157N > V162M > L129F > N161T (Figure 25 and Table 4).
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Figure 24: Rab7CMT2B mutants show enhanced EGFR phosphorylation
(A) Samples from EGFR degradation assays were probed for phospho-EGFR with actin
as the loading control. (B) Films from at least three independent experiments were
quantified by Image J analysis. Line graphs show levels of phospho-EGFR in GFP-Rab7
wild-type and CMT2B mutant expressing cells. In each case the amount of phosphoEGFR was normalized to the amount of total actin. Values in all cases are from three
independent experiments plotted ± S.E.M. Asterisks denote p<0.05 based on one-way
ANOVA with Dunnett’s post-test and relative to Rab7 wild-type control. Non-linear
curve fits were used to analyze degradation rates and obtain half-lives in Graphpad Prism
version 5.0.
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Figure 25: Rab7CMT2B mutants show delayed EGFR dephosphorylation. Samples
from EGFR degradation assays were probed with antibody against tyrosine 1045 of
EGFR to analyze the rate of dephosphorylation of the EGFR in the given time points.
Line graphs represent the levels of phosphorylated EGFR normalized to actin.
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Table 4: Half lives of activated EGFR, p38 and ERK1/2 in stable HeLa cells
expressing the GFP-Rab7 wild-type and CMT2B mutants on EGF stimulation
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Rab7CMT2B mutants show no significant changes in Akt phosphorylation on NGF
stimulation
The effect of NGF stimulation on the second major downstream signaling pathway
regulated by phosphorylation of Akt was also analyzed in PC12 cells transiently
expressing the Rab7CMT2B
mutants. There was no significant change in the Akt phosphorylation levels in the cells
expressing the disease mutants when compared to cells expressing GFP alone or GFPRab7 (Figure 26A–B). The activation of Akt was similar in all samples at early time
points and diminished uniformly at 24h.
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Figure 26: Cells expressing Rab7CMT2B mutants have no effect on Akt Signaling.
(A) Transiently transfected PC12 cells expressing GFP, GFP-Rab7, GFP-Rab7L129F,
GFP-Rab7K157N, GFP-Rab7N161T, GFP-Rab7V162M were briefly stimulated with
NGF (200ng/ml) followed by surface stripping of ligand and reincubation in 0.1% BSADMEM for 2-24h. Subsequently, cells were lysed and equal amounts of protein were
immunoblotted and probed for total and phosphorylated Akt. (B) Films from three
independent experiments were quantified by Image J analysis. Bar graph shows levels of
pAkt in GFP-Rab7 and CMT2B mutant expressing cells. In each case the amount of pAkt
was normalized to the amount of GFP protein expressed. The bar graph shows the foldchange in pAkt as a function of pAkt in the GFP only control at each respective time
point. Error bars indicating mean ± S.E.M. n=3, p values were not significant.
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The findings are in agreement with a previous observation indicating that NGF
stimulated Akt signaling occurs at the cell surface and is not triggered on the endosomes
(95). The combined data suggest that alterations in TrkA downstream signaling are
confined to endosomes and the ERK module, and are independent of Akt. Recent report
suggested that Akt activation is typically triggered at the plasma membrane and is
dependent on EGFR internalization. The MAPK activation in EGFR internalization
defective mutants were not affected thereby reiterating the point that MAPK activation
occurs from the internalized signaling endosomes (96).
Rab7CMT2B mutants expressing PC12 cells and HeLa show enhanced ERK signaling on
growth factor stimulation
Upon NGF stimulation, PC12 cells stop proliferating and start differentiating (97). NGFmediated TrkA signaling in PC12 cells typically activates ERK1/2 and Akt downstream
signaling. The ERK activation module is located on endosomes (95, 98, 99) and is
instrumental in NGF stimulated differentiation signaling from TrkA containing
endosomes (100). To investigate the activation of the ERK1/2 signaling mediators, PC12
cells transiently expressing Rab7CMT2B mutants were briefly stimulated with NGF
followed by surface stripping of ligand. Compared to control cells expressing GFP only
or GFP-Rab7 wild-type protein, PC12 cells expressing the GFP-tagged Rab7CMT2B
mutants consistently showed 1.5–2.2 fold higher levels of phosphorylated ERK1/2 at all
time points examined (Figure 27A-B, numerical values are provided in Table 2),
providing evidence for the higher levels of phosphorylated receptors leading to enhanced
downstream signaling.
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Figure 27: Cells expressing Rab7CMT2B mutants exhibit prolonged ERK signaling
following NGF stimulation. (A) Transiently transfected PC12 cells expressing GFP,
GFP-Rab7wild-type, GFP-Rab7L129F, GFP-Rab7K157N, GFP-Rab7N161T, GFP-Rab7
V162M were briefly stimulated with NGF (200ng/ml) followed by surface stripping of
ligand and reincubation in 0.1% BSA-DMEM for 2-24h. Subsequently, cells were lysed
and equal amounts of protein were immunoblotted and probed for total and
phosphorylated ERK1/2. (B) Films from three independent experiments were quantified
by Image J analysis. Bar graph shows levels of pERK1/2 in GFP-Rab7wt and CMT2B
mutant expressing cells. In each case the amount of pERK1/2 was normalized to the
amount of GFP protein expressed. The bar graph shows the fold-change in pERK1/2 as a
function of pERK1/2 in the GFP only control at each respective time point. Error bars
indicating mean ±S.E.M., n=3,*p<0.05; **p<0.01, ***p<0.001. For detailed numerical
values see Table 2.
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The effects of overexpression of Rab7CMT2B mutants on EGF-stimulated ERK1/2
signaling was assessed. HeLa cells and PC12 cells stably expressing the Rab7CMT2B
mutants were starved and stimulated with EGF in a time-dependent manner.
Rab7CMT2B mutants showed enhanced activation of p38 compared with the wild-type
in both the stable HeLa and PC12 cells overexpressing Rab7CMT2B mutants (Figure 28
A–D).
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Figure 28: Rab7CMT2B mutants show enhanced ERK1/2 activation. (A) HeLa cells
stably expressing GFP-Rab7 wild-type, GFP-Rab7L129F, GFP-Rab7K157N, GFPRab7N161T and GFP-Rab7V162M were starved with DMEM for 5h and stimulated with
EGF (100ng/ml) for indicated time points. Subsequently, cells were lysed and equal
amounts of protein were immunoblotted and probed for total and phosphorylated
ERK1/2.

(B)

Films

from

three

independent

experiments

were

quantified

densitometrically. Line graph shows levels of pERK1/2 in GFP-Rab7 wild-type and
CMT2B mutant expressing cells. In each case the amount of pERK1/2 was normalized to
the total ERK1/2 protein expressed. Differences are represented as ± S.E.M. (C) PC12
cells stably expressing GFP-Rab7 wild-type, GFP-Rab7L129F, GFP-Rab7K157N, GFPRab7N161T and GFP-Rab7V162M were starved in DMEM for 5h and stimulated with
EGF (100 ng/ml) for indicated time points. Subsequently, cells were lysed and equal
amounts of protein were immunoblotted and probed for total and phosphorylated
ERK1/2.

(D)

Films

from

three

independent

experiments

were

quantified

densitometrically. Line graph shows levels of pERK1/2 in GFP-WT Rab7 and CMT2B
mutant expressing cells. In each case the amount of pERK1/2 was normalized to the total
ERK1/2 protein expressed. Differences are represented as ± S.E.M. Asterisks denote
p<0.05 based on one-way ANOVA with Dunnett’s post-test and relative to Rab7 wildtype control.
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Quantification showed higher levels of phosphorylated ERK1/2 at all time points in the
cells expressing Rab7CMT2B mutants compared with the wild-type Rab7 (Figure 28 B
and D). The rates of dephosphorylation of activated ERK1/2 were up to 3.4-fold slower
in the CMT2B mutants as compared with the Rab7 wild-type (Table 4).
Rab7CMT2B Mutants Enhance p38 Activation
Previous studies have shown that overexpression of the GTP-locked Rab7Q67L mutant
leads to impaired degradation of EGFR with enhanced ERK1/2 signaling but no change
in p38 activation but reduced nuclear signaling (101). In contrast when p50/dynamitin
was overexpressed signaling endosomes were dispersed to the cell periphery were they
showed enhanced ERK1/2 and p38 activation, delayed EGFR degradation but enhanced
nuclear signaling. Although the Rab7CMT2B mutants are competent to bind GTP, their
phenotype in the EGFR trafficking assays was reminiscent of dominant negative Rab7,
overexpression of which impairs endocytic trafficking (102). To further study the effect
of overexpression of Rab7CMT2B mutants on EGF-stimulated endosomal signaling,
HeLa cells and neuronal PC12 cells stably expressing Rab7 wild-type or CMT2B mutants
were starved and stimulated with EGF in a time-dependent manner. Rab7CMT2B
mutants showed enhanced activation of p38 compared with the wild-type in both the
stable HeLa and PC12 cells overexpressing Rab7CMT2B mutants (Figure 29 A–D).
Quantification showed higher levels of phosphorylated p38 at all time points in the cells
expressing Rab7CMT2B mutants compared with the wild-type Rab7 (Figure 29 B and
D). The rates of dephosphorylation of activated p38 were up to 4.3-fold slower in the
CMT2B mutants as compared with Rab7 wild-type (Table 4).
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Figure 29: Rab7CMT2B mutants show enhanced p38 activation. (A) HeLa cells
stably expressing GFP-Rab7 wild-type, GFP-Rab7L129F, GFP-Rab7K157N, GFPRab7N161T and GFP-Rab7V162M were starved with DMEM for 5h and stimulated with
EGF (100 ng/ml) for indicated time points. Subsequently, cells were lysed and equal
amounts of protein were immunoblotted and probed for total and phosphorylated p38. (B)
Films from three independent experiments were quantified densitometrically. Line graph
shows levels of p-p38 in GFP-Rab7 wild-type (WT) and CMT2B mutant expressing
cells. In each case the amount of p-p38 was normalized to the total p38 protein expressed.
Differences are represented as ± S.E.M. (C) PC12 cells stably expressing GFP-WT Rab7,
GFP-Rab7L129F, GFP-Rab7K157N, GFP-Rab7N161T and GFP-Rab7V162M were
starved in DMEM for 5h and stimulated with EGF (100 ng/ml) for indicated time points.
Subsequently, cells were lysed and equal amounts of protein were immunoblotted and
probed for total and phosphorylated p38. (D) Films from three independent experiments
were quantified densitometrically. Line graph shows levels of phosphorylated p38 in
GFP-WT Rab7 and CMT2B mutant expressing cells. In each case the amount of
phosphorylated p38 was normalized to the total p38 protein expressed. Differences are
represented as ± S.E.M. Asterisks denote p<0.05 based on one-way ANOVA with
Dunnett’s post-test and relative to Rab7 wild-type control.
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Chapter 5: Rab7CMT2B mutants impair nuclear signaling
It is worth noting that the GTP-bound dominant active mutant of Rab7Q67L cause tight
perinuclear clustering of endosomes and delays the entry to late endosomes and hence the
degradation of internalized EGFR (101). As a consequence, the MAPK signaling is
sustained yet nuclear signaling is downregulated (decreased activation of Elk-1). In
contrast, repositioning the signaling endosomes containing activated internalized EGFR
to cell periphery by overexpressing p50/dynamitin, a dynein subunit results in sustained
MAPK signaling and enhanced nuclear signaling (increased activation of Elk-1). Thus
the appropriate trafficking of activated EGFR to endosomes controls the spatio-temporal
regulation of MAPK signaling (Figure 9). It is therefore necessary to measure the impact
of Rab7CMT2B mutants on the spatiotemporal fidelity of the endosomal signaling
relative to late endocytic traffic regulation.
Rab7CMT2B Mutants Decrease Elk-1-driven Gene Activation and Downstream c-fos
and Egr-1 Expression
Activated ERK1/2 translocates to the nucleus to activate the transcription factor Elk-1 to
drive gene activity (103). To investigate the impact of the enhanced endosomal activation
of p38 and ERK1/2 on nuclear signaling, HeLa cells stably expressing the Rab7CMT2B
mutants were co-transfected with plasmids encoding the Elk-1 and luciferase gene
controlled by the Elk-1-driven promoter. Following a 14h starvation, cells were
stimulated with EGF for 15–240min, and luciferase activity was measured. Cells
overexpressing the Rab7CMT2B mutants showed lower Elk-1-driven gene activity at all
time points compared with the cells overexpressing wild-type Rab7 (Figure 30).
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Figure 30: Rab7CMT2B mutants show lower Elk-1 driven gene activation and c-fos
and Egr-1 expression on EGF stimulation. (A) HeLa cells stably expressing GFPtagged wild-type (WT) Rab7 and CMT2B mutants were transfected with plasmids pFR
Luc and pFA2 Elk-1 to study Elk-1 driven gene activity. Cells were starved in DMEM
for 14h followed by EGF stimulation (100ng/ml) in a time dependent manner. Following
stimulation, cells were kept in serum free medium for 6h, lysed and luciferase activity
was determined in a luminometer. Each time point was performed twice and measured in
triplicates. Relative light units are normalized to the protein amounts. Disease mutants
showed lower Elk-1 driven gene activity. Rab7CMT2B mutants were compared to the
wild-type Rab7 at respective time points. Differences are represented as ± S.E.M. (B)
HeLa cells stably expressing GFP-Rab7 wild-type and CMT2B mutants were serum
starved, EGF stimulated for 1h and processed for RT-PCR as detailed in Experimental
Procedures. Bar graphs showing the lower expression of c-fos on EGF stimulation in cells
expressing GFP-Rab7CMT2B mutants compared to the wild-type. Differences are
represented as ± S.E.M. (C) Bar graphs showing the lower expression of Egr-1 on 1h
EGF stimulation in cells expressing GFP-Rab7CMT2B mutants compared to the wildtype. Differences are represented as ± S.E.M. (D,E) Bar graphs showing no difference in
expression levels of SMN1 and Mcl-1 on 1h EGF stimulation in cells expressing GFPRab7CMT2B mutants compared to the wild-type. Asterisks denote p<0.05 based on oneway ANOVA with Dunnett’s post-test and relative to Rab7 wild-type control.
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Although disease mutants exhibited enhanced ERK activation, the downstream Elk-1
target showed decreased activation. The altered Elk-1-driven gene activity in
Rab7CMT2B-expressing cells would be expected to influence downstream genes under
the transcriptional control of Elk-1. Therefore, we also analyzed the expression of two
genes directly targeted by active Elk-1, c-fos and Egr-1. Quantitative real-time PCR
analyses showed that all of the Rab7CMT2B mutants have significantly lower levels of cfos and Egr-1 gene expression compared with the wild-type following 1h of EGF
stimulation (Figure 30 B and C).however, not all genes that have important neuronal
functions and have been reported to be subject to Elk-1 regulation were uniformly
affected. There was no apparent decrease in SMN1 (survival- of-motor neuron 1) and
decreases in Mcl-1 (myeloid cell leukemia-1) transcription were too small to reach
statistical significance (Figure 30 D and E). This suggests that the CMT2B mutants
cause selective changes in Elk-1-regulated transcription.

Rab7CMT2B mutants expressing PC12 cells show altered subcellular localization of
phosphorylated ERK1/2 and p38 on growth factor stimulation
To examine the subcellular distribution of activated ERK1/2 on NGF stimulation in PC12
cells we used subcellular fractionation to separate the cytosolic and nuclear fractions.
Probing with lamin B, a nuclear envelope protein, tested the purity of the fractions.
Following brief NGF stimulation and surface stripping of ligand, cells expressing the
Rab7CMT2B mutants were reincubated in starvation medium for 2h and 24h. At the
shorter time point, the Rab7CMT2B mutant expressing cells showed diminished levels of
the activated ERK1/2 in the nucleus compared to GFP expressing control cells and
consequently predominant cytoplasmic distribution of activated ERK1/2 (Figure
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31A).however, after a 24h post stimulation chase period, activated ERK1/2 was no longer
detected in the nuclear fraction in either the Rab7CMT2B mutant or the wild-type Rab7
expressing cells (Figure 31B). Interestingly, the level of phosphorylated ERK1/2
remained higher in the cytosolic fraction of the disease mutants relative to cells
expressing the wild-type Rab7, suggesting either enhanced phosphorylation or decreased
dephosphorylation of the ERK1/2 in the cells expressing the disease mutants.
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Figure 31: Cells Expressing Rab7CMT2B Mutants Exhibit Altered Cytoplasmic and
Nuclear Partitioning of Activated ERK1/2. (A) Transiently transfected PC12 cells
expressing GFP, GFP-Rab7 wild-type, GFP-Rab7L129F, GFP-Rab7K157N, GFPRab7N161T, GFP-Rab7 V162M were briefly stimulated with NGF (200ng/ml) followed
by surface stripping of ligand and reincubation in 0.1% BSA-DMEM for 2h and (B) 24h.
Subsequently, cells were lysed and subjected to subcellular fractionation and
immunoblotted with antibodies directed against phosphorylated ERK1/2. The purity of
fractions was confirmed by probing for the nuclear marker lamin B.
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Figure 32: Rab7CMT2B mutants show delayed nuclear shuttling of activated
MAPKs in HeLa cells. (A) Stable HeLa cells expressing GFP-tagged wild-type (WT)
and Rab7CMT2B mutants were serum starved for 5h and stimulated with EGF (100
ng/ml) for 15min and 30min respectively. Subsequently, cells were lysed, subjected to
subcellular fractionation to separate the cytosolic (C) and nuclear (N) fractions and
immunoblotted with antibodies directed against phosphorylated p38 and phosphorylated
ERK1/2. The purity of fractions was confirmed by probing for the nuclear marker lamin
B. Rab7CMT2B mutants showed an impaired nuclear translocation of p-p38. Rab7L129F
and Rab7K157N showed an impaired translocation of pERK1/2 and to a lesser extent in
Rab7N161T and Rab7V162M expressing cells. (B, C) Bar graphs showing the
differences in the nuclear to cytoplasmic ratio of activated p38 and ERK1/2 following
15min and 30min of EGF stimulation. Differences are represented as ± S.E.M. Asterisks
denote p<0.05 based on one-way ANOVA with Dunnett’s post-test and relative to Rab7
wild-type control.

Comparison between CMT2B mutants was based on one-way

ANOVA with Tukey’s post-test and showed L129F significantly different from N161T
and V162M for p38 activation at 15min of EGF stimulation, p<0.05.
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Therefore it was tested if a similar delay in nuclear translocation of activated p38 and
ERK1/2 exists in response to EGF signaling and might account for the observed decrease
in Elk-1-driven gene activity in the disease mutants. HeLa cells and neuronal PC12 cells
stably expressing the GFP-tagged Rab7CMT2B mutants were serum starved and
stimulated with EGF for 15 and 30min prior to subcellular fractionation to separate the
nuclear and cytosolic fractions. ERK1/2 nuclear translocation was impaired most
significantly in the L129F and K157N mutants and to a lesser extent in the N161T and
V162M mutants. Activated p38 nuclear translocation was markedly delayed in cells
expressing all of the Rab7CMT2B mutants. The nuclear marker Lamin B and actin (not
shown) served as a control for purity of the nuclear and cytosolic fractions. In both the
HeLa (Figure 32) and PC12 (Figure 33) cells stably expressing the Rab7CMT2B
mutants, the nuclear/cytoplasmic ratio of activated p38 distribution was significantly
lower than in cells expressing Rab7 wild-type . Furthermore, in HeLa cells, Tukey’s
posthoc test showed that the nuclear/cytoplasmic ratio of activated p38 was significantly
lower in the L129F mutant compared with N161T and V162M mutants. In PC12 cells, no
statistically significant differences were observed between the individual CMT2B
mutants. Similar trends were observed for the distribution of activated ERK1/2 (Figure
32C and 33C). These results indicate that the Rab7CMT2B mutants have similar effects
in different cell lines in impairing nuclear signaling.
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Figure 33: Rab7CMT2B mutants show delayed nuclear shuttling of activated
MAPKs in neuronal PC12 cells. (A) Stable PC12 cells expressing GFP-tagged wildtype (WT) and Rab7CMT2B mutants were serum starved for 5h and stimulated with EGF
(100ng/ml) for 15min and 30min respectively. Subsequently, cells were lysed, subjected
to subcellular fractionation to separate the cytosolic (C) and nuclear (N) fractions and
immunoblotted with antibodies directed against phosphorylated p38 and phosphorylated
ERK1/2. The purity of fractions was confirmed by probing for the nuclear marker lamin
B. Rab7CMT2B mutants showed an impaired nuclear translocation of p-p38 and
pERK1/2. (B, C) Bar graphs showing the differences in the nuclear to cytoplasmic ratio
of activated p38 and ERK1/2 following 15min and 30min of EGF stimulation.
Differences are represented as ± S.E.M. Asterisks denote p<0.05 based on one-way
ANOVA with Dunnett’s post-test and relative to Rab7 wild-type control. Comparison
between CMT2B mutants based on one-way ANOVA with Tukey’s post-test showed no
significant differences between the mutants.
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Chapter 6: Results-Rab7CMT2B mutants alter ubiquitination of
activated growth factor receptors
Disease mutants of Rab7 occur predominantly in the GTP-bound state. Active Rab7
binds to different effector proteins. The disease mutants of Rab7 showed enhanced
interaction with different interactor proteins like ORP1L, Vps13c and clathrin heavy
chain compared to the wild-type (47). This implies that Rab7CMT2B mutants would be
expected to have differential interaction with a host of effectors. One such interactor is
XAPC7, an alpha subunit of proteasome, that interacts specifically with Rab7 and
colocalizes with it on the endosomal membrane thereby providing a link between
cytoplasmic and lysosomal degradation pathways (80).
Interestingly trafficking of activated TrkA receptor is mediated by a scaffolding protein
called p62/SQSTM1 that shuttles the ubiquitylated TrkA cargo to the proteasome for
deubiquitination (Figure 8). This step is a prerequisite for the lysosomal degradation of
the activated, internalized TrkA (72). SQSTM1/p62has been shown to colocalize with
late endosomal markers like Rab7 and Lamp1 and EGFR following EGF stimulation and
internalization (104). It is thus postulated that Rab7CMT2B mutants differentially
interact with XAPC7 and have a delayed association with p62 for deubiquitylating the
internalized, activated TrkA cargo creating a bottleneck that results in the observed delay
in degradation. p62 has been shown to colocalize with endosomal markers. It is thus
postulated a complex of Rab7, XAPC7 and p62 form a complex at late endosomal
membrane and regulate trafficking of growth factor receptors.
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Rab7CMT2B mutants are postulated to delay growth factor receptor trafficking. Since
p62 serves as a shuttling scaffold to deubiquitinate the ubiquitylated cargo prior to
lysosomal degradation, Rab7CMT2B mutants would be expected to delay this process.
To further dissect the mechanism responsible for the delayed degradation of growth
factor receptors upon expression of Rab7CMT2B mutant proteins, we analyzed the
ubiquitination status and interactions with proteasomal linker p62 protein.
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Figure 34: Expression of Rab7CMT2B mutants causes accumulation of
ubiquitinated TrkA.
Stable cell lines expressing wild-type Rab7 or Rab7CMT2B mutants were serum starved
and stimulated with nerve growth factor receptor for various times (0-360min). Cell
lysates were prepared, immunoprecipitated for TrkA, and probed for ubiquitinated
receptor at each time point. n=3.
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A possible link through the proteasomal degradative pathway is suspected because the
CMT2BV162M mutant failed to interact with the Rab7 interacting protein and alpha
proteasome subunit, XAPC7 (68, 80,81).
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Figure 35: Two adjacent Rab7CMT2B mutants differentially affect binding to
XAPC7, an alpha proteasome subunit XAPC7. (A) BHK-21 cells were transfected
with plasmids encoding full length human XAPC7 in combination with GFP-tagged
wild-type and Rab7CMT2B mutants. BHK-21 cell lysates were immunoprecipitated with
rabbit antibody directed against Rab7 and the immunoprecipitated samples were resolved
by 12 % SDS-PAGE and immunoblotted for XAPC7 and Rab7. (B) The data from three
experiments were quantified by densitometry (normalizing to the respective GFP-Rab7
signal) and the average is shown in the bar graphs. Error bars represent S.E.M. (C) A431
cells were co-transfected with XAPC7 plasmid and Rab7 wild-type or Rab7CMT2B
mutants as described in Experimental Procedures. Samples were resolved by SDS-PAGE
and then subjected to immunoblotting to detect EGFR and actin as a control. Same
samples were examined for XAPC7 expression level using mouse antibody.
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The results suggest that the endosomal traffic is not completely blocked in the presence
of endogenous wild-type protein but instead is slowed. Such a phenotype is consistent
with the slow but progressive nature of CMT2B disease. One possible mechanism for the
delayed transport could be differential Rab7 effector protein interactions with the
Rab7CMT2B mutants and could account for the autosomal dominant phenotype (Figure
34).
Expression of all four CMT2B mutants was found to prolong the lifetime of
ubiquitinated nerve growth factor receptor, TrkA relative to wild-type Rab7 expression
(Figure 34). All mutants except V162M exhibited reduced colocalization and interaction
with the TrkA proteasomal linker protein p62 (Figure 36). Therefore, p62 interaction is
crucial for chaperoning the ubiquitinated TrkA for proteasomal degradation.
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Figure 36: Rab7CMT2B mutants differentially colocalize with and interact with
proteasome linker p62. (A) Stable cell lines expressing GFP-tagged wild-type Rab7 or
Rab7CMT2B mutants (green) were immunostained for p62 (red). (B) Cell lysates were
prepared from stable cell lines expressing wild-type Rab7 or Rab7CMT2B mutants. Rab7
was immunoprecipitated from each cell lysate and immunoblotted for co-precipitation of
p62. As a control for equal immunoprecipitation and loading the same samples were also
immunoblotted for Rab7. (C) Quantification of three independent experiments as detailed
under (B).
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The role of p62 in TrkA trafficking in CMT2B mutants suggests an intersection with
autophagy. A recent report showed that Rab7V162M mutant colocalized with p62 in
enlarged vesicles and increased the anterograde transport of these autophagosomes
indicating an alteration in autophagic flux (105). This calls for an in depth analysis on the
putative role of p62 in altering the endosomal traffic in CMT2B disease conditions.
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Chapter 7: Discussion

Genome wide analysis of CMT disease have identified many important gene products
that play crucial role in axonal trafficking and misregulated functions of which lead to
CMT pathology (106-113,113-116). The Charcot-Marie-Tooth Type 2B disease
specifically involves mutations in conserved amino acid residues of the late endocytic
regulator Rab7. The four missense mutations of Rab7 implicated in the disease show
similar biochemical properties that have been associated with the proteins being
predominantly in the GTP-bound state (29, 30).
Rab7CMT2B mutants alter endocytic transport
Charcot-Marie-Tooth type 2B disease occurs due to L129F, K157N, N161T and V162M
substitutions in the ubiquitously expressed Rab7 protein. A perplexing mystery of the
Rab7 mutations is that only the peripheral nerves are affected even though Rab7 is a
ubiquitous protein. This has been attributed to the presence of one or more specific
effectors of Rab7 that affect unique pathways in the peripheral neurons to cause the
disease (48). The Rab7CMT2B mutants being predominantly in the GTP-bound state
have been suggested to cause more rapid degradation of the endocytosed growth factor
receptor (117),however, the results suggest slowed membrane cycling of Rab7CMT2B
mutants, which is directly linked to slowed trafficking and degradation of endocytosed
growth factor receptors, leading to enhanced and prolonged endosomal signaling. A
possible explanation for slowed transport is a differential interaction of Rab7CMT2B
mutants with downstream effector proteins. Previous studies have indicated enhanced
interaction of Rab7L129F and Rab7V162M mutants with cholesterol sensor ORP1L,
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Vps13C, and clathrin heavy chain (47). A recent report also suggests enhanced
interaction of all the four Rab7CMT2B mutants with peripherin, a neuronal intermediate
filament which alters its assembly dynamics (118). The Rab7CMT2B mutants have also
been found to phosphorylate and alter the assembly of vimentin, another intermediate
filament component (119).
Evidence for altered effector binding and differential phenotypes between other CMT2B
mutants is provided by other published studies and this thesis. Rab7K157N mutant does
not interact with the retromer complex, Vps35/29/26. This was the first report of a loss of
function for the Rab7K157N disease mutant and led to the postulate that neuronal
degeneration might result from altered retromer regulation of endosomal membrane
protein sorting. The Rab7CMT2B mutants, including the K157N mutant, are autosomal
dominant mutants; CMT2B patients harboring the K157N mutation would still possess
the wild-type Rab7, but the disease mutant would affect the kinetics of VPS35/29/26
recruitment, leading to reduced efficiency of endosomal protein sorting, which could be
detrimental in the very long axons that are affected in CMT2B patients (38). On early
endosomes, Rab7 functions in cargo sorting by recruiting the retromer complex (Vps26/
29/35), which enables retrieval of cation-independent mannose 6-phosphate receptor,
TGN38, Wntless among other cargo from early endosomes to the Golgi (38, 120, 121)
(Figure 5). Interaction of retromer with Snx proteins and actin-binding proteins couples
sorting with membrane tubulation (121, 122). Dysregulation of retromer is associated
with neurologic diseases, including Alzheimer’s disease, underscoring the importance of
the Rab7-retromer link.
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In fact, work in this thesis also shows a loss of function of Rab7V162M mutant based on
its diminished interaction with the Rab7 interactor alpha proteasomal subunit, XAPC7.
XAPC7 has been shown to be a negative regulator of endocytic transport (80), and the
impaired interaction with Rab7V162M mutant caused a relatively faster degradation of
internalized growth factor receptor compared with the other disease mutants. In
cytototoxic T-lymphocytes, Rab7V162M mutant showed more tightly clustered lytic
granules around the centrosome compared with those of the wild-type, although increased
dynein recruitment was not observed (123). It maybe postulated that such allele-specific
differences may account for kinetic differences between the mutants and help to reveal
mechanistic information about Rab7-effector interactions. However, allele specific
differences in the ability of the Rab7CMT2B mutants to bind various effectors cannot
solely be at the root of the common pathology seen in all Rab7CMT2B mutations. The
effects that are common to the different alleles (e.g. altered EGFR signaling/degradation)
are most likely to be informative regarding the pathologic mechanisms.

Rab7CMT2B mutants alter endosomal signaling
This thesis shows that Rab7CMT2B mutants alter endosomal signaling. Here it is
demonstrated that the Rab7CMT2B mutants enhance ERK signaling in response to both
NGF and EGF triggered signaling through cognate receptors. This enhanced ERK
signaling is likely to be dependent on the endosomal membrane residence time of the
activated TrkA and EGFR, which is in turn regulated by Rab7. Being predominantly in
the GTP-bound state the Rab7CMT2B mutants would be expected to promote more rapid
degradation of the TrkA containing signaling endosomes. Consequently, the net effect of
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slowed trafficking of the activated TrkA caused by Rab7CMT2B mutants present on
endosomes is entirely consistent with the observed enhancement of phosphorylated
ERK1/2 in all cell types. Brief stimulation of PC12 cells expressing the disease causing
Rab7CMT2B mutants with NGF did not significantly affect Akt phosphorylation. There
have been reports of the presence of activated Akt in various cell organelles such as
nucleus, Golgi apparatus, cell surface and mitochondria, although not endosomes (124,
125). Therefore, consistent with previous work showing Akt signaling predominates at
the plasma membrane (67,95), the data show Akt signaling does not emanate from
endosomes containing activated TrkA.
An intriguing question that remains is the role played by the MAP kinase phosphatases
(MKPs) in regulating the level of phosphorylated ERK1/2. MKP3 expression is triggered
by the translocation of the activated ERK to the nucleus, is maximal around 3h after NGF
stimulation and the upregulation can last as long as five days in PC12 cells (126). MKP3
is cytoplasmic and acts specifically on ERK (127). Because the disease associated
Rab7CMT2B mutants lead to significantly higher levels of activated ERK1/2, the
negative regulatory function that is normally met through the MKP activity is likely
compromised in CMT2B disease. The results suggest that the impaired neurite growth,
which is an important disease phenotype, may be due in part to retardation of shuttling of
the phosphorylated ERK1/2 to the nucleus, which is normally a prerequisite for
upregulation of MKP3 expression and down regulation of ERK signaling (97).
The strong persistence of phosphorylated ERK1/2 24h after brief NGF stimulation was
reported previously in PC12 cells expressing the GDP-bound Rab7T22N mutant (67).
The expression of the Rab7T22N mutant, which is stabilized in inactive state, did not
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however preclude nuclear localization of the activated ERK1/2. Furthermore, inhibition
of Rab7 activity by overexpressing the Rab7T22N was shown to trigger neurite
outgrowth in PC12 cells following brief NGF stimulation (67). In contrast, it is
demonstrated that the Rab7 mutants associated with CMT2B disease led to accumulation
of the phosphorylated ERK1/2 in the cytosol rather than the nucleus. This may explain
the inhibitory effect of the Rab7CMT2B mutants on neurite outgrowth as recently
observed (117).
Sensory neurons have very long axons and endocytosis typically occurs at the distal
axonal terminal. Signaling endosomes must therefore traverse a long way to the cell body
via retrograde transport and consequently misregulation of the Rab7 cycle under diseased
conditions (e.g. mutant versions of Rab7) would lead to altered trafficking and deficits in
the translocation of activated ERK1/2. This could account for the more pronounced
effects of these mutants in cells bearing longer neurites (>0.50µm) (117). The
accumulation of activated ERK1/2 in the cytoplasm suggests that the CMT2B associated
mutants retard kinase shuttling to the nucleus, which is required to upregulate the genes
responsible for differentiation of sensory neurons. An alternative explanation stems from
a recent study showing the enhanced trafficking of Rab7CMT2B positive
endosomes/autophagosomes in the anterograde direction rather than the usual retrograde
direction that might increase the membrane residence time of the MAPK signaling
scaffold and account for the enhanced cytoplasmic signaling observed in this study (105).
The data shed new light on the mechanism mediating the deficits in neurite outgrowth in
Charcot-Marie-Tooth disease.
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Previous studies have shown that overexpression of the constitutively active Rab7Q67L
mutant causes a perinuclear accumulation of endosomes that delays the delivery of EGFR
to the late endosomes and subsequent EGFR degradation. Additionally, ERK signaling
was enhanced, whereas p38 signaling decreased (101). It was also seen the Rab7CMT2Bpositive endosomes to be more concentrated in the perinuclear region although not quite
as tightly clustered as the Rab7Q67L-positive endosomes, which might partially explain
the enhanced p38 and ERK activation and slower EGFR degradation. Also the
positioning of the signaling endosomes decorated by the Rab7CMT2B mutants seems to
play a crucial role in determining the signal output. Enhanced endosomal p38 and
ERK1/2 activation may reflect slowed membrane sequestration of the internalized
activated growth factor receptor into intralumenal vesicles. The relatively higher
membrane residence time of Rab7CMT2B mutants suggested by FRAP experiments
accounts for an increased residence time of the MAPK scaffold, in turn accounting for
the enhanced ERK1/2 and p38 activation following growth factor stimulation of
Rab7CMT2B mutant expressing cells. In PC12 cells, EGF stimulation results in transient
MAPK activation in contrast to NGF signaling, where sustained activation of MAPK
continues signaling by phosphorylating transcription factors. These differential
consequences of signaling determine the proliferative (EGF-induced) and differentiation
(NGF-induced) capacity of the cell (128). Interestingly, EGFR family members have also
been shown to function in concert, autonomously or non-autonomously, to regulate the
development of the peripheral nervous system (129-132). Hence, impaired trafficking of
internalized epidermal growth factor receptors can reduce nuclear signaling and
expression of immediate early genes to cause an overall developmental defect. The
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experiments conducted in this dissertation work show a similar defect in nuclear shuttling
of activated ERK1/2 upon NGF stimulation in PC12 cells expressing the Rab7CMT2B
mutants (68). All four Rab7CMT2B mutants showed differential nuclear to cytoplasmic
distribution of activated ERK upon NGF stimulation of TrkA receptors compared to the
wild-type. The effects of EGF stimulation in non-neuronal HeLa and neuronal PC12 cells
were also analyzed. Indeed, nuclear distribution of the signaling MAPKs was reduced, as
also observed for TrkA signaling (133). The data are consistent with a prolonged half-life
of activated pEGFR due to delayed trafficking to lysosomes, linked to the prolonged
membrane residence time of the mutant Rab7 proteins and a concomitant increased
membrane residence time of the MAPK scaffold.

Rab7CMT2B mutants show impaired nuclear signaling
This thesis also shows a reduced nuclear signaling with lower Elk-1 driven gene activity
and lower transcription of c-fos and Egr-1 in the disease mutants, most likely due to the
impaired nuclear shuttling of activated p38 and ERK1/2 in the disease mutants. It is
worth noting that another member of the Egr family, Egr-2 is mutant in CMT1D and 4E
types. Interestingly, Egr-1 and Egr-2 show 92% sequence homology in the zinc binding
finger structure (134) that might explain a common mechanism operative in different
types of CMT disease.
Elk-1 uses different DNA binding modes to regulate distinct classes of target genes
involved in cellular processes ranging from cytoskeletal regulation to apoptosis (135).
For example, transcription of SMN1 is dependent on ETS-domains in Elk-1 rather than
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on serum response factor element recognition, as well as on glycogen synthase kinase
3(136, 137). This may explain why no impact of the CMT2B mutants on SMN1
transcription was observed. Mcl-1 is a prosurvival factor that regulates autophagy in
mature neurons via a Rab7-Beclin-dependent pathway (136, 138). Although Mcl-1 is also
subject to transcriptional regulation by Elk-1, reductions in Mcl-1 transcription were too
slight to reach statistical significance in our experimental system but might be more
critical in a neuronal context with long axons.

Rab7CMT2B mutants differentially interact with p62 and show slower deubiquitination
of TrkA receptors
The co-immunoprecipitation studies demonstrate an altered interaction of p62 with the
Rab7CMT2B mutants. SQSTM1/p62 lies at the nexus of TrkA endocytic trafficking and
autophagy. Hence a correlative alteration of these two machineries in CMT2B disease
cannot be ruled out. In fact a recent report suggests modulation of the endocytic and
autophagic flux by the Rab7CMT2B mutants that substantially increase the transport of
these vesicles in the anterograde direction compared with the wild-type Rab7. The speed
of TrkA transport was significantly decreased in the vesicles containing the Rab7CMT2B
mutants (105). This thesis also suggests a slower process of deubiquitination of the TrkA
receptors in the Rab7CMT2B mutants which would suggest an impaired shuttling of the
ubiquitylated TrkA from the late endosomes to the proteasome for deubiquitination by
the p62 and hence a delay in TrkA transport and lysosomal degradation.
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Conclusion
Overall, the results suggest an impaired trafficking and altered endosomal and nuclear
signaling in cells expressing the Rab7CMT2B mutants and lay the foundation for a better
understanding of the disease pathology. Rab7, although a ubiquitous protein, affects
principally the peripheral nervous system in CMT2B disease. The more pronounced
effect of the CMT2B mutants in reducing nuclear translocation of p38 and ERK1/2 in
PC12 cells might be attributed to neuronal cell-specific effectors and/or a greater
sensitivity to defects in endocytic trafficking, as suggested previously (31, 48).
In conclusion, the study throws light on the pathogenic mechanism leading to CharcotMarie-Tooth Type2B disease by defining the enhanced Rab7-dependent activation of
TrkA and EGFR and the consequent alteration of downstream MAPK signaling pathways
that leads to altered nuclear signaling and overall impaired transport.
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Future Directions
Charcot-Marie-Tooth disease typically manifests in the second or third decade of life.
Impaired trafficking of growth factor receptors may over time alter the balance between
proliferative and differentiation signals that cause axonal shortening and eventual loss of
contacts necessary for viability. Peripheral axons can grow as long as 1meter, and
impairment in long distance transport from the axonal tip to the cell body through
differential interaction of Rab7 with specific effector proteins may impair endosomal
traffic and in turn affect endosomal and nuclear signaling to cause progressive
neurodegeneration. Dynein-/dynactin-mediated perinuclear positioning of late endosomes
have also been shown to depend on the membrane-associated scaffolding protein,
huntingtin (Htt), which when mutant causes Huntington’s disease, though the link
between Htt and Rab7 remains unclear (31, 139). Htt and the huntingtin associated
protein of 40 kDa (HAP40) are known effectors of Rab5 that facilitate transfer between
microtubule-and actin-based networks. Parallel in vitro studies testing Rab7 did not
provide evidence for a direct Rab7-Htt or a Rab7-HAP40 interaction, although
huntingtin-associated protein 1 (HAP1) binds dynactin-p150-Glued (31). Therefore, it is
speculated that Htt interaction with the Rab7 dynein/dynactin complex may occur
through HAP1. In light of the disease relevance, further study of the potential interfaces
between Htt,HAP1 and Rab7 is warranted. Although no difference was found in the
interaction between Rab7CMT2B mutants and its effector the RILP that bridges between
endosomes and the dynein-dynactin motor complex (29), future work should carefully
examine the role played by the kinesin motors in enhancing the anterograde transport of
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these Rab7CMT2B mutant-vesicles as recently reported (105). This might help
investigate the molecular basis of CMT2B pathology.
The similarities between CMT diseases and hereditary spastic paraplegia, together with
the recent identification of single nucleotide polymorphisms or SNPs in Rab7 that are
linked to late onset Alzheimer disease (140), suggest that these findings may be more
broadly relevant to other neurodegenerative diseases.
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Appendices
Appendix A: Small molecule intervention of Rab7 activity
Therapeutic interventions relevant to CMT2B disease remain unexplored. To date
there is only one report that suggests therapeutic intervention with the small molecule
mood stabilizer drug, valproic acid. In DRG neurons expressing the Rab7CMT2B
mutants, valproic acid was found to improve defective neurite formation via the c-Jun
N terminal Kinase (JNK) signaling pathway (141). Valproic acid is a histone
deacetylase inhibitor that promotes neuronal differentiation through extracellular
signal regulated kinase (ERK) and glycogen synthase kinase 3 (GSK 3) pathways
(142). Direct interventions of Rab GTPases through modulation of membrane
association, nucleotide binding or exchange and inhibition of protein-protein
interaction remain unexploited. There is only one report that used a systematic screen
for Rab7 guanine nucleotide binding inhibitors where purified proteins immobilized
on beads were used to assay for fluorescent GTP binding by flow cytometry
(Appendix A) (31). As mentioned earlier, the inhibitor of Rab7 identified in our lab
reports an inhibition of GTP binding of 80% and GDP binding of 60% in vitro (87).
Inhibition of Rab7 guanine nucleotide binding would be expected to significantly
impair its interaction with effector proteins in cells by this novel approach. Targeting
the activity of Rab7CMT2B mutants that predominantly occur in the GTP-bound
active state would hence regulate the signaling pathways that get altered due to
impaired trafficking in axons.
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Appendix A: Bead based flow cytometry assay to analyze the effect of small
molecule inhibition of Rab7 activity
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Appendix B: Rab GTPase activation in response to growth factor
stimulation measured in flow cytometry based assay
A robust bead-based assay is devised to quantitatively monitor GTPase protein-protein
interactions and also assess Rab GTPase activation in response to growth factor
stimulation (Figure 11). The assay is novel, adaptable to multiplexing and sensitive
enough for measuring GTPase activity in small cell lysate samples. The assay provided
the first concrete evidence for an upregulation in Rab5 and Rab7 GTPase activity in
response to growth factor (EGF) signaling. While there have been reports that Rab7 is
phosphorylated in response to EGF stimulation it has long been assumed that EGF and its
receptor are constitutively endocytosed. The time course of increased Rab5 and Rab7
activation is directly correlated with the known time course of endocytosis. Rab5 is
required for early events in endocytosis from the plasma membrane to early endosomes
and Rab7 being required at later stages when cargo moves from early endosomes to late
endosomes and lysosomes.
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Appendix B: Quantitative Flow Cytometry Assay for measuring Rab GTPase
activation status in cells. Bar graphs: Purified GST-effector proteins (EEA1 for Rab5
and RILP for Rab7) were bound to GSH beads overnight in HPSE buffer (HPS, 1mM
EDTA, and 0.1% BSA). Cells were serum-starved and stimulated with 10ng/ml EGF for
2min to 4h and cell lysates prepared in RIPA buffer. Lysates were immediately incubated
with effector beads, and bound, active Rab5 or Rab7 GTPases were quantified using
fluorescently conjugated antibodies against Rab5 or Rab7.

Negative controls with

irrelevant antibody were measured in parallel and subtracted prior to calculation of fold
change. n=3.
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Appendix C: Effector Binding Assay Reveals Cellular Inhibition of Rab
GTPases by CID1067700
As detailed above, a flow cytometry assay was established based on effector binding that
can specifically measure Rab5 and Rab7 in the GTP-bound states. The assay was used to
definitively demonstrate that the compound is effective in inhibiting Rab5 and Rab7 in
cells. The findings confirm that the observed inhibition of EGFR degradation in cell
based assays is a direct consequence of GTPase inhibition.
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Appendix C. A novel competitive inhibitor of Rab7 blocks Rab GTPase activation
in cells. Cells were serum-starved and EGF-stimulated with or without CID1067700, a
competitive inhibitor of Rab7. A flow cytometric effector binding assay was used to
quantify the levels of active Rab5 (EEA1 used as effector) and Rab7 (RILP used as
effector). n=3.
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Appendix D: CID1067700 impair EGFR degradation in HeLa cells
stably expressing GFP-tagged Rab7
HeLa cells were serum starved for 2h followed by EGF stimulation in a time dependent
manner. Cells treated with CID1067700 showed slower EGFR degradation.
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Appendix D: A novel competitive inhibitor of Rab7, CID1067700 impairs EGFR in
cells. Cells were serum-starved and EGF-stimulated with or without CID1067700, a
competitive inhibitor of Rab7. Following EGF stimulation for the indicated time points
cells were lysed and samples were immunoblotted and probed for anti-EGFR antibody.
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Appendix E: Rab7 inhibitor CID1067700, inhibits autophagy
To further investigate the role of CID1067700 in impairing Rab7 activity, cells were
starved for 2h followed by 1h treatment with CID1067700 and its structural analogs, CID
46916263 and CID 1251121. The levels of LC3-II, an indicator of autophagy were
quantified. The Rab7 small molecule inhibitor showed higher level of accumulation of
LC3-II.
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Appendix E: Rab7 inhibitor CID1067700 inhibits autophagy. A) HeLa cells starved
for 2h with Earle’s Balanced Salt Solution (EBSS) were treated with CID1067700,
CID46916263 and CID1251121 for 1h. Cells were lysed and probed with anti LC3
antibody. B) Densitometric quantification of the blots were quantified by Image J
analysis. LC3-II levels were normalized against actin. Differences are represented as ±
S.E.M. Asterisks denote p<0.05 based on one-way ANOVA with Dunnett’s post-test and
relative to Rab7 wild-type control.
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Conclusion
The detailed mechanisms of alteration of endocytic trafficking and signaling in CMT2B
disease are still beginning to be appreciated. However therapeutic intervention of Rab7
might help ameliorate the trafficking defects observed in CMT2B disease but this
endeavor is still at its nascent stage. To date, CID1067700 is the only small molecule
inhibitor functionally characterized that has the potential to modulate Rab7 activity as a
competitive inhibitor (87). This is promising as Rab7CMT2B mutants predominantly
exist in the GTP-bound state and any therapeutic intervention to regulate the GTP loading
on the nucleotide binding pocket of these Rab7CMT2B mutants would be expected to
help prevent the molecular trafficking events that go awry in CMT2B disease. Future
studies should focus on testing the efficacy of this molecule on animal models
recapitulating the CMT2B disease and translate to clinical trials.
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